Formulation and Evaluation of Orodispersible Tablets of Metoclopramide Hydrochloride. by Nilesh Chindhu, Patil
 
 
 
FORMULATION AND EVALUATION OF ORODISPERSIBLE 
TABLETS OF METOCLOPRAMIDE HYDROCHLORIDE 
 
A Dissertation submitted to 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY, CHENNAI, 
In partial fulfillment of the requirement for the award of the degree of 
 
MASTER OF PHARMACY 
(PHARMACEUTICS) 
 
Submitted By 
Registration No: 26104216 
 
Under the guidance of 
K. RAJA, M. PHARM. (Ph.D.)., 
Department of Pharmaceutics 
 
 
 
 
SEPTEMBER 2012 
NANDHA COLLEGE OF PHARMACY AND RESEARCH INSTITUTE 
ERODE – 638 052 
TAMILNADU 
 
 
 
Prof. K. RAJA. M. Pharm. (Ph.D.) 
Department of Pharmaceutics,  
 
Nandha College of Pharmacy, Erode-638 052 
 
      
CERTIFICATE 
 
                                                                                                              
This is to certify that the work embodied in this thesis entitled, “FORMULATION AND 
EVALUATION OF ORODISPERSIBLE TABLETS OF METOCLOPRAMIDE 
HYDROCHLORIDE” submitted to The Tamil Nadu Dr. M.G.R. Medical University, Chennai, 
was carried out by Mr. NILESH CHINDHU PATIL, Department of Pharmaceutics, Nandha 
College of Pharmacy, Erode-52 for the partial fulfilment for the award of degree of Master of 
Pharmacy in Pharmaceutics under my supervision. 
 This work is original and has not been submitted in part or full for any other degree or 
diploma of this or any other university. 
 
 
 
    Place: Erode                                                            Prof. K. RAJA M. Pharm., (Ph.D.) 
    Date:                                                                        Department of Pharmaceutics 
   
                          
 
 
 
 
 
 
 
 
EVALUTION CERTIFICATE 
 
This is to certify that the work embodied in this thesis entitled “FORMULATION AND 
EVALUATION OF ORODISPERSIBLE TABLETS OF METOCLOPRAMIDE 
HYDROCHLORIDE” submitted to the Tamil Nadu Dr. M.G.R. Medical University Chennai, 
was carried out by Mr. NILESH CHINDHU PATIL in the department of pharmaceutics, 
Nandha College of Pharmacy, Erode-52 in the partial fulfilment of the degree of “Master of 
Pharmacy” in pharmaceutics under supervision of Prof. K. RAJA M. Pharm. (Ph.D.)., Prof. 
Pharmaceutics department, Nandha College of Pharmacy, Erode-52. 
This work is original and has not been submitted in part or full for the award of any other 
degree or diploma of any other University. 
 
   
Internal Examiner                                            External Examiner 
 
 
Convener of Examination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DECLARATION 
The work presented in this thesis entitled “FORMULATION AND EVALUATION OF 
ORODISPERSIBLE TABLETS OF METOCLOPRAMIDE HYDROCHLORIDE” was 
carried out by me in the Department of Pharmaceutics, Nandha College of Pharmacy, Erode-52 
under the direct supervision of Prof. K. RAJA M. Pharm, (Ph.D.), Prof. Pharmaceutics, 
Nandha College of Pharmacy, Erode-52. 
This work is original and has not been submitted in part or full for the award of any other 
degree or diploma of any other University. 
 
 
 
Place: Erode                                                                                              Reg. No: 26104216 
Date:                                                                                                            M. Pharm. II Year 
                                                                                                                        Pharmaceutics 
                                                                                                           Nandha College of Pharmacy 
                                                                                                           and Research Institute, Erode. 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENT 
Any successful task is not an individual’s effort but it is joint venture of many people. It 
would not be justifiable to forget those people’s dedication and efforts while sailing in the boat 
of success, so now this is a time to thank all of them whose kindness, support and guidance has 
brought my project work possible. 
My first and foremost appreciation is extended to my true and encouraging guide Prof. 
K. RAJA M. Pharm, (Ph.D.), professor Department of Pharmaceutics Nandha College of 
Pharmacy, Erode, for his valuable guidance, keen interest, inspiration, unflinching 
encouragement and moral support throughout my dissertation work make my task successful and 
complete. 
It is a pleasure to express my sincere gratitude to Dr. T. Shivakumar, Principal, Nandha 
College of Pharmacy, Erode, with a deep sense of gratitude for his constant support, 
encouragement, cooperation, kind suggestions and providing the best facilities during this work. 
I express my deepest thanks to Mr. Thiru V. Shanmugan, B. Com., Chairman and Mr. 
S. Nandhakumar Pradeep, M.B.A., Secretary, Nandha College of pharmacy, Erode-52, for 
providing all the facilities to make this work a success. 
It is my privilege to express my heartfelt thanks to my co-guide Mr. N.T. Mahajan, Plant 
Manager and Mr. V.R. Zope, R & D Incharge JCPL PHARMA LTD., Jalgaon. For providing 
all the facilities and precious guidance in carrying out my work. 
I would like to give special thanks to colleague of JCPL PHARMA LTD., Jalgaon. who 
helped me a lot while working in the industry. 
I express my sincere thanks to Dr. S. Tamilzharasi, M. Pharm., Ph.D., HOD, 
Department of Pharmaceutics, Nandha College of Pharmacy, Erode, for providing much of 
 
 
efforts in the form of suggestions, guidance, and encouragement throughout the course of this 
thesis. 
I owe my warmest and humble thanks to Prof. Jagdeeshwaran, M. Pharm, Asst. Prof. 
Dept. Pharmaceutical Analysis and Dr. Sengotuvelu, M. Pharm., Ph.D. Head of the Dept. of 
Pharmacology and Prof. R. Rajvel M. Pharm., Dept. of Pharmaceutical Chemistry and Dr. 
Durai Swami M. Pharm. Ph.D. Asst. Prof. Dept. of Pharmacognosy,  for their immense help 
throughout the course of study. 
I also express my deepest thanks to respected teachers Dr. P. R. Radhika, M. Pharm.  
Ph.D., Asst. Prof. Dept. of Pharmaceutics and Mrs. P. Amsa M. Pharm., Asst. Prof. Dept. of 
Pharmaceutics, who constantly support me throughout the course of study. 
I extend a special thanks to the entire non-teaching staff and Balu, Lab Asst. of 
Pharmaceutics, for their kind help and co-operation throughout the course. 
I am very much thankful to my seniors and friends Sagar, Dilip, Madhukar, Nilesh, 
Bhushan, Pankaj, Subhash, Prakash for giving proper guidance, constant support and co-
operation. 
How can I forget my lots of friends who travelled to my life path, some of them are 
unforgettable. I am very thankful to god to have real friends Kishor, Kundan, Vishal, Hemant, 
Niranjan, Vivek, Shahu boosted up my spirits with their love, care and moral support and make 
every task easy. 
I express my heartfelt thanks to my brother, Avinash Patil for providing me moral 
support, constant inspiration and encouragement. 
 
 
At last but not least are ‘My Parents’. There are no words to express my gratitude to my 
parents for lifting me up till the phase of life. They give all support in every task to reach 
completion. I owe everything to them. 
I am thankful to all those people who spend their valuable time for guiding me 
throughout these two years. 
 
 
 
Place: Erode                                                                   Reg. No.: 26104216  
Date:                                                                               M. Pharm. II Year 
                                                                                        Pharmaceutics 
                                                                                        Nandha College of Pharmacy 
                                                                                        and Research Institute, Erode.           
 
 
 
    
 
 
 
                                                     
 
 
 
CONTENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr.No TITLE Page. no 
1. INTRODUCTION 01-17 
2. REVIEW OF LITERATURE 18-26 
3. AIM AND OBJECTIVE 27-28 
4. PLAN OF WORK 29-30 
5. DRUG PROFILE 31-33 
6. EXCIPIENTS PROFILE 34-51 
7. MATERIALS AND METHODS 52-64 
8. RESULTS AND DISCUSSION 65-88 
9. SUMMARY AND CONCLUSION 89-90 
10. REFERENCES 91-94 
 
 
LIST OF ABBREVIATIONS 
 
 
 
Abbreviations Abbreviation Terminology 
ODTs Oro-dispersible tablet 
GERD Gastro Esophageal Reflux Disease 
CTZ Chemo Receptor Trigger Zone 
FTIR Fourier Transform Infra-Red 
USP United States Pharmacopoeia 
NF National Formulary 
IP Indian Pharmacopoeia 
BP British Pharmacopoeia 
IR Infra-Red 
UV Ultraviolet 
HCL Hydrochloric acid 
Ac-Di-Sol Croscarmellose Sodium 
MCC Microcrystalline cellulose 
0
C Degree Celsius 
% Percentage 
W/V Weight by volume 
W/W Weight by weight 
Ml Milliliter 
Cm Centimeter 
Mm Millimeter 
Nm Nanometer 
Mg Milligram 
Gm Gram 
µg Microgram 
Kg Kilogram 
T Time 
pH Hydrogen ion concentration 
Hrs Hours 
Sec Second 
Min Minutes 
SD Standard Deviation 
Rpm Revolutions per minute 
RH Relative Humidity 
 
 
1. INTRODUCTION 
 Oral route of drug administration is the most common and preferred method of delivery 
as it is the simplest and easiest way of administering drugs. The rout offers ease of drug 
administration in a convenient manner and patients are more familiar with this rout. So, patient 
compliance and thus drug treatment is typically more effective with orally given 
medications.¹The tablet is most widely used dosage form existing today because of its 
convenience in term of self administration, compactness and ease in manufacturing. However, 
geriatric, paediatric and mentally ill patients experiences difficulty in swallowing conventional 
tablets, which is common among all age groups, especially in elderly which leads to poor patient 
compliance. To overcome these problem, scientists have developed innovative drug delivery 
system known as mouth dissolving or disintegrating tablets. This dosage forms dissolve and 
disintegrates in the oral cavity within minutes without need of water or chewing. This 
formulation is useful in administration of drug in paediatric and geriatric patients.
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1.1 Orodispersible Tablet 
 The most popular solid dosage formsare being tablets and capsules, one 
important drawback of this dosage forms for some patients, is the difficulty to swallow. Drinking 
water plays an important role in the swallowing of oral dosage forms. Often times people 
experience inconvenience in swallowing conventional dosage forms such as tablet when water is 
not available, in the case of motion sickness (kinetosis) and sudden episodes of coughing during 
the common cold, allergic condition and bronchitis. For these reason, tablets that can rapidly 
dissolve or disintegrate in the oral cavity have attracted a great deal of attention. Orodispersible 
tablets are not only indicated for people who have swallowing difficulties, but also ideal for 
active people. Orodispersible tablets are also called as mouth-dissolving tablets, melt-in mouth 
tablets, fast dissolving tablets, rapimelts, porous tablets, quick dissolving etc. Orodispersible 
tablets are those when put on tongue, disintegrates instantaneously, releasing the drug, which 
dissolve or disperses in the saliva. The faster the drug into solution, quicker the absorption and 
onset of clinical effect. Some drugs are absorbed from the mouth, pharynx and oesophagus as the 
saliva passes down into stomach. In such cases, bioavailability of drug is significantly greater 
than those observed from conventional tablet dosage form. The advantages of mouth dissolving 
 
 
dosage forms are increasingly being recognized in both, industry and academics. Their growing 
importance was underlined recently when European pharmacopoeia adopted the term 
“Orodispersible tablet” as a tablet that to be placed in the mouth where it disperses rapidly before 
swallowing.
3
 
 
Figure 1.1: Mechanism of action of orodispersible tablet 
 United States Pharmacopoeia has also approved for these dosage form as 
orodispersible tablets. Thus, orodispersible tablets are solid unit dosage forms like conventional 
tablets, but are composed of super disintegrants, which help them to dissolve the tablets within a 
minute in the mouth in the presence of saliva without any difficulty of swallowing. It offers 
several advantages with respect to its stability, administration without water, accurate dosing, 
easy manufacturing, small packaging size, and handling. Its ease of administration in the 
population especially for paediatric, geriatric, or any mentally retarded persons makes it a very 
popular dosage form. Due to the presence of superdisintegrants, it gets dissolved quickly, 
resulting in rapid absorption of drug which in turn provides rapid onset of action. Since the 
absorption taking place directly from the mouth, so, bioavailability of the drug increases. Drugs 
present in orodispersible tablets are also not suffering from first pass metabolism. This type of 
drug delivery is becoming popular day by day due to its numerous advantages.
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 The oral rout remains the preferred route for administration of therapeutic 
agents because of accurate dosage, low cost therapy, self medication, non invasive method and 
ease of administration leading to high level of patient compliance. However, traditional tablets 
and capsules administered with a glass of water may be inconvenient or impractical for some 
geriatric patients because of changes in various physiological and neurological conditions 
associated with aging including difficulty in swallowing/dysphagia, hand tremors, deterioration 
in their eyesight, hearing, memory, risk of choking in addition to change intaste and smell. For 
these reasons, it is said that age is a convenient „red flag‟ that pharmacists can use to alert 
themselves for patients who may have special counselling needs. Solid dosage forms also present 
significant administration challenges in other patient groups, such as children, mentally 
challenged, bed ridden and uncooperative patients. Paediatric patients may suffer from ingestion 
problems as a result of underdeveloped muscular and nervous control. Moreover, patients 
travelling with little or no access to water, limit utility of orally administered conventional tablets 
or capsules. Therefore, to cater the needs of such patients, recent advancements in technology 
have resulted in development of viable dosage alternatives popularly known as orally 
disintegrating tablets (ODTs). These dosage forms are preferable alternative for oral medication 
in improving the quality of life and patient acceptability. ODTs are the solid unit dosage 
form/entities containing medicinal substances which disintegrate or dissolve rapidly in oral 
cavity usually within a few seconds even without the need of water or chewing. As the tablet 
disintegrate in mouth, this can enhance the clinical effect of drug through pregastric absorption 
from the mouth, pharynx and esophagus. The advantages of these dosage forms are continuously 
and increasingly being identified in both pharmaceutical industries as well as in academia.
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 The most important drug delivery route is undoubtedly the oral route. It 
offers advantages of convenience of administration and potential manufacturing cost savings. 
Drugs that are administered orally, solid oral dosage forms in general and tablets in particular 
represent the preferred class of product. Today drug delivery companies are focusing on solid 
oral drug delivery systems that offer greater patient compliance and effective dosages. Over a 
decade, the demand for development of orally disintegrating tablets (ODTs) has enormously 
increased as it has significant impact on the patient compliance. Orally disintegrating tablets 
offer an advantage for populations who have difficulty in swallowing. It has been reported that 
dysphagia (difficulty in swallowing) is common among all age groups and more specific with 
 
 
paediatric, geriatric population along with institutionalized patients and patients with nausea, 
vomiting, and motion sickness complications. ODTs with good taste and flavour increase the 
acceptability of bitter drugs by various groups of population.
6
 
i) Definition  
        The US Food and Drug Administration Center for Drug Evaluation and Research 
(CDER) defines, in the „Orange Book‟, an ODT as “a solid dosage form containing medicinal 
substances, which disintegrates rapidly, usually within a matter of seconds, when placed upon 
the tongue”. The significance of these dosage forms is highlighted by the adoption of the term, 
“Orodispersible Tablet”, by the European Pharmacopoeia which describes it as a tablet that 
can be placed in oral cavity where it disperses rapidly before swallowing.
7
 
 Orodispersible tablets are those when put on tongue, disintegrates instantaneously, releasing 
the drug, which dissolves or disperses in the saliva. The faster the drug into solution, quicker the 
absorption and onset of clinical effect.
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ii) Need to formulate orodispersible tablets 
 The need for non-invasive drug delivery systems continues due to patients poor acceptance 
and compliance with existing delivery regimes, limited market size for drug companies and drug 
uses coupled with high cost of disease management. ODT is one such dosage form which is 
useful for geriatric patients mainly suffering from conditions like hand tremors and dysphasia. 
 
 Paediatric patients who are unable to swallow easily because their central nervous 
system and internal muscle are not developed completely. 
 Travelling patients suffering from motion sickness and diarrhoea that do not have 
easy access to water. 
 Especially for patients with persistent nausea for a long period of time are unable to 
swallow. 
 Mentally challenged patients, bedridden patients, and psychiatric patients. 
iii)  Limitation of ODTs 
 Drugs with relatively larger doses are difficult to formulate into ODTs e.g. antibiotics 
like ciprofloxacin with adult dose tablet containing about 500mg of the drug. 
 Patients who concurrently take anticholinergic medications may not be the best 
candidates for ODTs. 
 
 
 Patients with sjogrens syndrome or dryness of mouth due to decreased saliva 
production may not be good candidates for these tablet formulations.
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iv)  Criteria for Orodispersible Drug Delivery System 
The tablets should : 
 Not require water to swallow, but it should dissolve or disintegrate in the mouth in 
matter of seconds. 
 Be compatible with taste masking. 
 Be portable without fragility concern. 
 Have a pleasing mouth feel. 
 Leave minimal or no residue in the mouth after oral administration. 
 Exhibit low sensitivity to environmental conditions as humidity and temperature. 
 Allow the manufacture of tablet using conventional processing and packaging 
equipments at low cost.
3
 
v)  Salient Features of Orodispersible Drug Delivery System 
 Ease of administration to patient who refuses to swallow a tablet, such as paediatric 
geriatric patients and psychiatric patients. 
 No need of water to swallow the dosage form, which is highly convenient feature for 
patients who are travelling and do not have immediate access to water. 
 Rapid dissolution and absorption of drug, which will produce quick onset of action. 
 Some drugs are absorbed from mouth, pharynx and oesophagus as the saliva passes 
down into the stomach; in such cases bioavailability of drugs increased.
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vi) Advantages of ODTs 
 Rapid onset of action and may offer an improved bioavailability. 
 Improved patient compliance. 
 Useful for paediatric, geriatric and psychiatric patients. 
 Suitable during travelling where water may not be available. 
 No specific packaging required, can be packaged in push through blisters. 
 Smooth mouth feel and pleasant taste. 
 Conventional manufacturing equipment. 
 
 
 Cost effective. 
 Good chemical stability as conventional oral solid dosage form. 
 Convenience of administration and accurate dosing as compared to liquid 
formulations. 
 More rapid drug absorption from the pre-gastric area i.e. mouth, pharynx and 
oesophagus which may produce rapid onset of action. 
 Pre-gastric absorption can result in improved bioavailability, reduced dose and 
improved clinical performance by reducing side effects. 
 Beneficial in case such as motion sickness, suede-episodes of allergic attack (or) 
coughing, where an ultra rapid onset of action required. 
 Portable without fragility concern. 
 Advantageous over liquid medication in terms of administration as well as. 
 First pass metabolism is reduced, thus offering improved bioavailability and thus 
reduced dose and side effects. 
 Offering improved safety.8 
vii) Disadvantages of ODTs 
 Orodispersible tablet is hygroscopic in nature so must be keep in dry place. 
 Some time it possesses mouth feeling. 
 ODT require special packaging for properly stabilization and safety of stable 
product.
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1.2 Superdisintegrants 
                         Disintegrating agents are substances routinely included in the tablet formulations 
to aid in the break-up of the compacted mass into the primary particles to facilitate the 
dissolution or release of the active ingredients when it is put into a fluid environment. They 
endorse moisture penetration and dispersion of the tablet matrix. The major function of 
disintegrants is to oppose the efficiency of the tablet binder and physical forces that act under 
compression to structure the tablet. Recently new material termed as “superdisintegrants” have 
been developed to improve the disintegration processes. 
 
 
 
  Figure 1.2 : Disintegration mechanism of superdisintegrant materials. 
1.2.1 Selection of Superdisintegrants :-  
 Since supredisintegrant is used as an excipient in the tablet formulation, it has to meet certain 
criteria other than its swelling properties. The requirement placed on the tablet disintegrant 
should be clearly defined. The ideal disintegrant should have- 
1) Poor solubility. 
2) Poor gel formation. 
3) Good hydration capacity. 
4) Good moulding and flow properties. 
5) No tendancy to form complexes with the drugs. 
6) Good mouth feel. 
7) It should also be compatible with the other excipients and have desirable tableting 
properties. 
1.2.2 Advantages of Superdisintegrants 
1) Effective in lower concentrations than starch. 
2) Less effect on compressibility and flow ability. 
3) More effective intragranularly. 
1.2.3 Mechanism of Superdisintegrants 
 Superdisintegrants are used to improve the efficacy of solid dosage forms. This is achieved 
by various mechanisms. The mechanism by which the tablets are broken into small pieces and 
then produces a homogeneous suspension is based on : 
1) Swelling 
 
 
2) Porosity and capillary action (wicking) 
3) Heat of wetting 
4) Chemical reaction (Acid-Base reaction) 
5) Particle repulsive forces 
6) Deformation recovery 
7) Enzymatic reaction 
1) Swelling 
Swelling is probably the most widely accepted mechanism of action for tablet disintegrants. 
Particles of disintegrant swell on coming in contact with suitable medium and a swelling force 
develop which leads to break-up of the matrix. Tablets with high porosity show poor 
disintegration due to lack of adequate swelling force. On the other hand, sufficient swelling force 
is exerted in the tablet with low porosity. It is worthwhile to note that if the packing fraction is 
very high, fluid is unable to penetrate in the tablet and disintegration is again slows down. 
2) Porosity and capillary action (Wicking) 
      Effective disintegrants that do not swell are believed to impart their disintegrating action 
through porosity and capillary action. Tablet porosity provides pathways for penetration of fluid 
into tablets. When we put the tablet into suitable aqueous medium, the medium penetrates into 
the tablet and replace the air adsorbed on the particles, which weakens the inter molecular bond 
and breaks the tablet into fine particles. Water uptake by tablet depends upon hydrophilicity of 
the drug / excipient and on tableting conditions. For these type of disintegrants maintenance of 
porous structure and low interfacial tension towards aqueous fluid is necessary which helps in 
disintegration by creating a hydrophilic network around the drug particles. 
                                                            
 Particles swell, volume increases                                   Liquid is drawn up into the 
 to break apart the tablet, swelling                                   pores and rupture the inter   
 sets up localised stress spread                                         particulate bonds causing the 
 throught the matrix.                                                        tablet to break apart.    
 
Figure 1.3 :Disintegration of tablets by swelling and wicking mechanism. 
3) Heat of wetting 
When disintegrants with exothermic properties get wetted, localised stess is created due to 
capillary air expansion which aids in disintegration of tablet. This explanation, however, is 
 
 
limited to only a few types of disintegrants and can not describe the action of most modern 
disintegrating agents. 
4) Chemical reaction (Acid-Base Reaction) 
The tablet is quickly broken apart by internal liberation of co2 in water due to interaction 
between tartaric acid and citric acid (acids) with alkali metal carbonates or bicarbonates (bases) 
in presence of water. The tablet disintegrates due to generation of pressure within the tablet. Due 
to lberation of co2 gas, the dissolution of active pharmaceutical ingredients in water as well as 
taste masking effect is enhanced. As these disintegrants are highly sensitive to small changes in 
humidity level and temprature, strict control of environment is requiredduring preparation of the 
tablets. The effervescent blend is either added immediately prior to compression or can be added 
in two separate fraction of formulation. 
5) Particle repulsive forces 
This is another mechanism of disintegration that attempts to explain the swelling of tablet 
made with non-swellable disintegrants. According to Guyot-Hermann‟s particle-particle 
repulsion theory, water penetrates into tablet through hydrophilic pores and a contineous starch 
network is created that can convey water from one particle to the next, imparting a significant 
hydrostatic pressure. The water then penetrates between starch grains because of its affinity for 
starch surface, there by breaking hydrogen bonds and other forces holding the tablet together. 
The electric repulsive forces between particles are the mechanism of disintegration and water is 
required for it. 
6) Deformation recovery 
Deformation recovery theory implies that the shape of disintegrant particles is distorted during 
compression and the particles return to their pre-compression shape upon wetting, there by this 
increase in size of the deformed particles causing the tablet to break apart. Such a phenomenon 
may be an important aspect of the mechanism of actio of disintegrants such as corspovidone and 
starch that exhibit little or no swelling. 
 
 
 
 
Water is drawn into the pores                                       Particles swells to pre-compression  and 
particles repel each other                                       size and break up the matrix of the becaues of 
the resulting electrical force.                         tablet.  
               Figure 1.4 : Disintegration of tablets by repulsion and deformation mechanism. 
7) By enzymatic reaction 
Enzymes present in the body also act as disintegrants. These enzymes dearth the binding 
action of binder and helps in disintegration. Due to swelling, pressure is exerted in the outer 
direction that causes the tablet to burst or the accelerated absorption of water leads to an 
enormous increase in the volume of granules to promote disintegration. 
Table No. 1.1 : Disintegrating Enzymes 
Enzyme Binder 
Amylase Starch 
Protease Gelatin 
Cellulase  Cellulose and its derivatives 
Invertase Sucrose 
 
1.3 Various technologies used in the manufacture of ODT 
The performance of ODT depends on the technology used in their manufacture. The orally 
disintegrating property of the tablet is attributable to a quick ingress of water into the tablet 
matrix, which creates porous structure and results in rapid disintegration. Hence, the basic 
approches to develop ODT include maximising the porous structure of the tablet matrix, 
incorporating the appropriate disintegrating agent and using highly water soluble exipients in the 
formulation. Following technologies have been used to prepare ODT- 
 
 
1. Freeze-Drying or Lyophilization. 
2. Tablet Moulding. 
3. Spray Drying. 
4. Sublimation. 
5. Direct Compression. 
6. Mass-Extrusion. 
1) Freeze-Drying or Lyophilization 
Freeze drying is the process in which water is sublimed from the product after it is frozen. 
This technique creates an amorphous porous structure that can dissolve rapidly. A typical 
procedure involved in the manufacturing of ODT using this technique is mentioned here. The 
active drug is dissolved or dispersed in an aqueous solusion of a carrier/polymer. The mixture is 
dosed by weight and poured in the wells of the preformed blister packs. The trays holding the 
blister packs are passed through the liquid nitrogen freezing tunnel to freeze the drug solution or 
dispersion. Then the frozen blister packs are placed in the refrigerated cabinets to continue freeze 
drying. After freeze drying the aluminium foil backing is applied on a blister sealing machine. 
Finally the blisters are packged and shipped. The major disadvantages of lyophilization 
technique are that it is expensive and time consuming; fragility makes conventional packgaing 
unsuitable for these products and poor stability under stressed conditions. 
2) Tablet Moulding 
 The preparation of ODT using moulding technology employs water soluble ingredients so 
that the tablet dissolves completely and rapidly. The active ingredients in most cases are 
absorbed through the mucosal lining of the mouth. Moulding process is of two type‟s i.e. solvent 
method and heat method. Solvent method involves moistening the powder blend with a 
hydroalcoholic solcent follwoed by compression at low pressures in moulded plates to form a 
wetted mass (compression moulding). The solvent is than removed by air drying. The tablets 
manufactured in this manner are iess compact than compressed tablets and posses a porous 
structure that hastens dissolution. The heat moulding process involves preparation of a 
suspension that contains a drug, agar and sugar (e.g.mannitol or lactose) and pouring the 
suspension in the blister packaging wells, solidifying the agar at the room temprature to form a 
jelly and drying at 30
0
 under vaccum. The mechanical strength of molded tablets is a matter of 
great concern.Binding agents, which increase the mechanical strength of the tablets, need to be 
 
 
incorporated. Taste masking is an added problem to this technology. To overcome this, Van 
Scoik incorporated taste masked drug particles. The taste masked drug particles were prepared 
by spray congealing a molten mixture of hydrogenated cottonseed oil, sodium bicarbonate, 
lecithin, polyethylene glycol and an active ingredient into a lactose based tablet triturate form. 
Compared to the lyophilization technique, talets produced the by molding technique are easier to 
scale up for industrial manufacture. Masaki uses an agar solution as a binding agent and a blister 
packaging as well as a mold to prepare an intra buccally fast disintegrating tablet. 
3) Spray Drying 
Spray drying is used in pharmaceutical industries to produce highly porous powdres. The 
pocessing solvents is evaporated rapidly by spray drying, which renders the product highly 
porous and thus can be used in manufacturing ODT. In this technique, gelatin can be used as a 
supporting agent and as a matrix, mannitol as a bulking agent and sodium starch glycolate or 
cross carmellose or crospovidone are used as superdisintegrants. Tablets manufactured form the 
spray-dried powder have been reported to disintegrate in less than 20 seconds in aqueous 
medium. Allen and wang have reported this technique for preparing fast dissolving tablets. The 
formulation contained bulking agent like mannitol and lactose, a superdisintegrant like sodium 
starch glycolate and crosscarmellose sodium and acidic ingredients (citric acid) and/or alkaline 
ingredients (e.g. sodium bicarbonate). This spray dried powder, which compressed into tablets 
showed rapid disintegration and enhanced dissolution. 
4) Sublimation 
This technique is based on the use of volatile ingredients (e.g. camphor, ammonium 
bicarbonate, naphthalene, urea, urethane etc.) to other tablet excipients and the mixture is then 
compressed into tablets. Entrapped volatile material is then removed via sublimation, which 
leads to formation of a porous structure. These compressed tablets which have high porosity 
(approximately 30%) rapidly dissolved within 15 seconds in saliva. Several solvents like 
cyclohexane, benzene etc. can also be used as pore forming agents. Orodispersible tablets with 
highly porous structure and good mechanical strength have been developed by this method. 
Koizumi et al. prepared highly porous compressed tablets. They used mannitol as a tablet 
matrix material while camphor as subliming agent. Camphor was removed by subliming in 
vaccume at 80
0
C for 30 minutes to develop pores in the tablets. 
 
 
Makino et al. described a method of producing a fast dissolving tablet using water as a pore 
forming material. They used a mixture containing active ingredient and carbohydrates (glucose, 
mannitol, xylitol etc) which then moistened with water (1-3%w/w) and compressed into tablets. 
Then water was removed, yielding highly porous tablet. 
 
 
Figure 1.5 : Steps involved in sublimation technique 
5) Direct Compression 
 It is the easiest way to manufacture tablets. Conventional equipments, commonly available 
excipients and limitated number of processing steps are involved in direct compression. Also 
high doses can be accommodated and final weight of tablet can easily exceed that of other 
production method. This technique can now be applied to fast dissoliving tablets because of the 
availability of improved tablet excipients, especially tablet disintegrants and sugar based 
excipients. Addition of disintegrants in fast dissolving tablets, leads to quick disintegration of 
tablets and hence improves dissolution. In many fast dissolving tablet technologies based on 
direct compression, the disintegrants principally affect the rate of disintegration and hence the 
dissolution. The introduction superdisintegrants and a better understanding of their properties 
have increased the popularity of this technology. Tablet disintegration time can be optimised by 
concentrating the disintegrants. Below critical concentration, tablet disintegration time is inversly 
proportional to disintegrants concentration. Above the critical concentration level, however, 
disintegration time remains approximately constant or even increases. 
 
 
Microcristalline cellulose, cross linked carboxymethyl cellulose sodium, cross linked 
polyvinyl pyrrolidone and partially substituted hydroxypropyl cellulose, through water insoluble, 
absorb water and swell due to capillary action and are considered as effective disintegrants in the 
preparation of fast dissolving tablets. Bi et al. and Watanbe et al. used microcristalline cellulose 
(MCC) and low substituted hydroxypropyl cellulose (HPC) to manufacture rpidly disintegrating 
tablets. The ratios of MCC to HPC varied from 8:2 to 9:1. Ito and sugihan investigated applying 
agar powder as a disintegrants because the powder absorbs water and swell considerably with 
forming a gel at physiological tempratures 
Fast disintegration of tablets can also be achived by incarporating effervescent disintegrating 
agents, which generates carbon dioxide. This phenomenon also resulted in partial taste masking 
of unacceptable taste of the drug. The major drawback of effervescent excipients is their 
hygroscopicity (i.e. the ability to absorb atmospheric moisture). Hence, their manufacture 
requires control of humidity conditions and protection of the final product. This is reflected by 
the overall cost of the product. 
Another approach to fast dissolving tablets or orodispersible tablets by direct compression is 
the use of sugar based excipients (e.g. dextrose, fructose, isomalt, maltitok, maltose, mannitol, 
sorbitol, starch hydrolyse, polydextrose and xylitol), which display high aqueous solubility and 
sweetness, and hence, impart taste masking and pleasing mouthfeel. 
 
 
 
Figure 1.6 : steps involved in direct compression technique 
6) Mass Extrusion 
In this technique, a blend of active drug and other ingredients is softened using solvent 
mixture of water soluble polyethylene glycol, using methanol and then softened mass is extruded 
through the extruder or syringe to get a cylinder of product, which is finally cut into even 
segments with the help of heated blades to get tablets. The dried cylinder can be used to coat the 
granules of bitter tasting drugs and thereby masked their bitter taste. 
1.4 Patented technologies for oral dispersible tablets 
 
 
The various technologies are developed for the preparation of orodispersible drug delivery 
system that are – 
1. Zydis technology. 
2. Durasolv technology. 
3. Orasolv technology. 
4. Flash dose technology. 
5. Wowtab technology. 
6. Flashtab technology. 
7. Oraquick technology. 
1) Zydis technology 
  Zydis, the best known of the fast dissolving/disintegrating tablet preparations, was the 
first marketed new technology tablet. The tablet dissolves in the mouth within seconds after 
placement on the tongue. A zydis tablet is produced by lyophilizing or freeze drying the drug in a 
matrix usually consisting of gelatin (Gregory et al, 1981 and Mizumoto et al, 1996). The product 
tablet is very lightweight and fragile and must be dispensed in a special blister pack. Patients 
should be advised not to push the tablets through the foil film, but instead peel the film back to 
release the tablet. The zydis product is made to dissolve on the tongue in 2 to 3 seconds. The 
zydis formulation is also self preserving because the final water concentration in a freeze dried 
product is too low to allow for microbial growth. A major claim of zydis product is increased 
bioavailability compared to traditional tablets. Because of its dispersion and dissolution in saliva 
while still in the oral cavity, there can be a substantial amount of pregastric absorption from this 
formulation. 
2) Durasolv technology 
Durasolv is cima‟s second generation fast dissolving / disintegrating tablet formulation. 
Produced in a fashion similar to orasolv, durasolv has much higher mechanical strength than its 
predecessor due to the use of higher compaction pressures during tableting. Durasolv tablets are 
prepared by using conventional tableting equipment and have good rigidity. The durasolv 
product is thus produced in a faster and more cost effective manner. Durasolv is so durable that it 
can be packaged in traditional blister packing, pouches or vials. (Mizumoto et al, 1996 and 
Mizumoto et al, 2003). One disadvantages of durasolv is that the technology is not compatible 
 
 
with larger doses of active ingredients, because the formulation is subjected to such high 
pressure on compaction. 
3) Orasolv technology 
Orasolv was cima‟s first dissolving dosage form. The orasolv technology unlike zydis dispers 
in saliva with the aid of almost imperceptile effervescence. The orasolv technology is best 
described as a fast dissolving tablet; the tablet matrix dissolves in less than one minute, leaving 
coated drug powder. The taste masking associated with the orasolv formulation is twofold. The 
unpleasant flavour of a drug is not merely counteracted by sweetners or flavour; both coating the 
drug powder and effervescence are means of taste masking in orasolv. This technology is 
frequently used to develop over the counter formulation, (wehling et al, 1996 and 1993). 
4) Flash dose technology 
A fuize technology has three oral drug delivery systems that are related to fast disslution. The 
first two generation of quick dissolving tablets, soft chew and ez chew, require some chewing. 
However, these paved the way for fuize‟s most recent development, flash dose technology. The 
flash dose technology utilizes a unique spinning mechanism to produce floss- like crystalline 
structure; much like cotton candy. This crystalline sugar can then incorporate the active and be 
compressed into the tablet. This procedure has been patented by fuize and is known as 
shearform. The final product has a very high surface area for dissolution. It disperses and 
dissolves quickly once placed onto the tongue. 
5) Wowtab technology 
The wowtab technology has been on the japanese market for a number of years. Wowtab 
technology is patented by Yamanouchi pharmaceutical co. The wow in wowtab signifies the 
tablet is to be given “with out water”. It has just recently been introduced into the US. The 
wowtab technology utilizes sugar and sugar – like (e.g. mannitol) excipients. This process uses a 
combination of low mouldability saccharides (rapid dissolution) and hihg mouldability 
saccharides (good binding property) the two type of saccharides are combined to obtain a tablet 
formulation with adequate hardness and fast dissolution rate due to its significants hardness, the 
wowtab formulation is a bit more stable to the environment than the zydis and orasolv 
(Mizumoto et al, 1996 and 2003). 
6) Flashtab technology 
 
 
Prographarm laboratories have patented the flashtab technology. This technology involves the 
preparation of rapidly disintegrating tablet which consists of an active ingredient in the form of 
microcrystal. Drug microgranules may be prepared by using the conventional techniques like 
coacervation, extrusion- spheronization, simple pan coatin methods and microencapsulation 
(cousin et al, 1995). The microcrystals of micogranules of the active ingredient are added to the 
granulated mixture of excipients prepared by wet or dry granulation and compressed into tablets. 
7) Oraquick technology 
The oraquick fast dissolving / disintegrating tablet formulation utilizes a patented taste 
masking technology. Kv pharmaceutical claims its microsphere technology, known as 
micromask, has a superior mouthful over taste masking alternatives. The taste masking process 
does not utilize solvents of any kind, and therefore leads to faster and more efficient production. 
Also, lower heat of production than alternative fast dissolving / disintegrating technologies 
makes oraquick appropriate for heat sensitive sterilization. 
 
Patented 
technology 
Basis of 
technology 
Technology developed 
by company 
Active ingredient 
Zydis Lyophilization R.p scherer , inc Loratidine 
Durasolv Direct 
compression 
Cima lab, inc Zolmitriptan 
Orasolv Direct 
compression 
Cima lab, inc Zolmitriptan 
Flashdose Cotton candy 
processs 
Fuize technology ltd. Tramadol 
Flashtab Direct 
compression 
Ethypharm Ibuprofen 
Wowtab Direct 
compression 
Yamanouchi pharma yech. 
Inc. 
Famotidine 
Oraquick Micromask taste 
masking 
Kv pharm Co. inc. Hyoscyamine sulphate 
mdt 
Table no. 1.2 : Patented technologies based branded products 
 
 
2. REVIEW OF LITERATURE 
 
Nitin Mohire et al., (2009) Metronidazole orodispersible tablets have been prepared by 
three different techniques of taste masking and three different disintegrating agents‟ viz. sodium 
starch glycolate (SSG), Bamboomanna (BB), Chitosan (CHN) and combination thereof. 
Metronidazole is a choice of drug in most of the oro-dental problems. The metallic taste and 
large dose size limits its use in dentistry. Pleasantly flavored and taste masked orodispersible 
metronidazole in tablet form helps to overcome these drawbacks and thereby increases patient 
compliance. The combination of SSG:BB and SSG:CHN in the proportion of 1:1 and have been 
found most effective in disintegrant property. Bamboomanna used alone did not show 
superdisintegrant property. However it when it was in combination with other established 
superdisintegrants, showed significant increase in disintegrant property. Complex formation of 
drug with glycerrhiza glabra extract showed good result of taste masking. 
B. G. Shiyani et al., (2009) Compare the disintegrants efficiency of the three 
superdisintegrants (Ac-De-Sol, Polyplasdone XL and Explotab) and also to compare the 
disintegrant properties and disintegrant efficiency of agar (AG) and gellan gum (GG) with 
treated agar (TAG) and treated gellan gum (TGG) by formulating Metoclopramide HCL 
immediate release tablets by direct compression method. Disintegration efficiency of powder 
disintegrants compared by swelling and hydration capacity of disintegrants. While efficiency of 
disintegrants in tablets compared by various test like disintegration time, dissolution test, wetting 
time and maximal water uptake study of metoclopramide HCL immediate release tablets. The 
rapid disintegration observed for the TAG and TGG containing tablets due to high porous 
structure of treated form of disintegrants which confirmed by photomicroscope study. 
Bhunia Biswajit et al., (2011) Have prepared orodispersible tablets of Amlodipine 
Besilate by using three different disintegrants like cross povidone (Polyplasdone XL 10), Sodium 
starch glycolate (SSG), Cross carmellose sodium (Ac-De-Sol). Two method of preparation are 
used to formulate the orodispersible tablet of amlodipine besilate like direct compression and 
sublimation method. And compare the dissolution profile of drug in two techniques. Comparison 
of two methods by using different superdisintegrants formulate the orodispersible tablet. 
Sublimation method showed good result as compare to direct compression. 
 
 
Sutradhar et al., (2012) Prepared taste masked oral dispersible tablets of Domperidone 
by sublimation method and investigate the effects of superdisintegrants (Kollidone CL) on the 
disintegration time as well as the percent release of a model drug from Kollidone 30, Ispaghula 
husk, and Guar Gum based formulation. Domperidone, an anti-emetic drug was taken as the 
model drug for the study. A high porosity was achieved using camphor as volatilizing agent 
which allowed easy penetration of dissolution media followed by rapid release of the drug. The 
granules and tablets were evaluated and found to be acceptable according to standard limits. In-
vitro release studies were performed using USP apparatus –II (paddle method) in 900 ml of 0.1N 
HCL (pH 1.2) at 50 rpm. The release mechanisms were explored and explained with different 
kinetic model. 
Honey Goel et al., (2008) Formulate fast disintegrating tablets (FDTs) for nausea and 
vomiting using aminoacetic acid, carmellose, and sodium alginate with enough mechanical 
strength. Ondansteron HCL (water soluble) or domperidone (water insoluble) drug were added to 
FDTs and their disintegration behaviour was evaluated. Placket Burman Screening Design was 
used to screen the dependent and independent variables for the drugs. Ondansteron HCL is 
soluble in water (1g in 3 ml) whereas dompridone is insoluble in water. Therefore, Ondansteron 
HCL and domperidone with different solubility profiles were selected for formulating FDTs 
containing aminoacetic acid, carmellose and sodium alginate. Thus, FDTs of these drugs will be 
helpful in rapid drug delivery, even without the intake of water, thereby alleviating nausea and 
vomiting sensation at an early stage. 
Anilkumar J. Shinde et al., (2009) Developed fast dissolving tablet of Cephalexin. A 
combination of superdisintegrants i. e. Sodium starch glycolate(SSG) and cross carmellose 
sodium (CS) were used along with camphor as a subliming material. An optimized concentration 
of camphor was added to aid the porosity of the tablet. The addition of flavor and sweetener 
impacts pleasant taste to the formulation. Full factorial design was applied to investigate the 
combined effect of two formulation variables amounts of SSG and CS. Infrared (IR) 
spectroscopy was performed to identify the physicochemical interaction between drug and 
polymer. IR spectroscopy showed that there is no interaction of drug with polymer. Alcoholic 
solution of polyvinyl pyrrolidone k-30 (PVP) was used to preparation of granules of physical 
mixture of drug, excipients and camphor. The granules were compressed into tablet using flat 
face single punch tablet machine. Camphor was sublimed from the tablet by exposing the tablet 
 
 
to vacuum drier at 60
0
 for 12 hrs. all the formulations were evaluated for their characteristics 
such as average weight, hardness, wetting time, friability, content uniformity, disintegration time 
and dissolution rate. 
Bhupendra G. Prajapati et al., (2010) Developed fast dissolving tablets of 
Domperidone by wet granulation method. Sodium Starch Glycolate, was taken as 
superdisintegrant and starch paste as a binder for the study. The domperidone (anti-emetic) is 
taken as the model drug for the study an wet granulation as a method of preparation of the fast 
dissolving tablet. The disintegrant may be incorporated during the wet granulation process as 
extra granular incorporation. Full factorial design was applied to investigate the combine effect 
of 2 formulation variables : Sperdisintegrants and starch paste. The concentration of 
superdisintegrants and concentration of starch paste were taken as independent variables, X1 and 
X2 respectively. And there effect of Disintegration time, wetting time Q30 and friability were 
investigated which are taken as dependent parameters. And also studied the efficiency of 
different sperdisintegrant for the wet granulation. 
Kulkarni et al., (2010) Developed fast dissolving tablets of Meloxicam by employing 
vacuum drying technique utilizing single and multi-volatile components. Analysis revealed that, 
formulation containing camphor and menthol as subliming agents yielded the best result in term 
of dissolution rate (M7). Result also revealed that, all the formulations had enough mechanical 
strength, good mouth feel and lesser wetting and disintegration time. Stability study indicates 
that upon storage disintegration and wetting time of tablets decreased significantly without losing 
their mechanical strength. 
Basawaraj S. Patil et al., (2011) Prepared fast dissolving tablets (FDTs) of Granisteron 
HCL by sublimation technique. Granisteron HCL is a selective 5-HT3 receptar antagonist, which 
may have beneficial therapeutic effects in the treatment of vomiting and nausea resulting from 
cancer therapy. The prepared formulation were evaluated for pre-compressional and post-
compressional parameters. The compatibility of drug with other ingredients was checked by 
FTIR studies , the result revealed that there was no interaction between drug and other 
excipients. The disintegration time of the tablets decreased significantly with increase in the 
concentration of subliming agent. 
Reeta et al., (2012) Review onrecent advancement in orally disintegrating preparations. 
Oral route is the most convenient route for the drug administration due to the highest component 
 
 
of compliance mainly the pediatrics and geriatrics. It is regarded as the most economical and 
safest method of drug delivery. Formulation of a orally disintegrating dosage form is beneficial 
for patients suffering from motion sickness, repeated emesis, mental disorder and dysphasia 
because they cannot swallow large quantity of water and it is easy to administer. The unique 
property of orally disintegrating dosage form is that they are readily disintegrating and dissolve 
in saliva and avoids requirement of water which is the major benefit over conventional dosage 
form. 
Rakesh Pahwa et al., (2010) studies of Orally Disintegrating Tablets - Friendly to 
Pediatrics and Geriatrics to obviate the problem of dysphagia and to improve patient compliance, 
ODTs have gained considerable attention as preferred alternatives to conventional tablet and 
capsule formulations these techniques render the disintegration of tablet rapidly and dissolve in 
mouth without chewing or additional water intake. 
Ashok Kumar et al., (2009) Developed orally disintegrating tablet of Terbutaline 
Sulphate for asthma by wet granulation technique. Asthma is defined simply as reversible airway 
obstruction characterized by attacks of breathlessness, tight chest, wheezing and coughing. 
Granules containing drug, diluent, subliming agents, aspartame were prepared by wet granulation 
technique using alcoholic solution of polyvinyl pyrrolidone K25 (10% w/v) as a binder. The 
dried granules were then mixed with lubricant magnesium stearate and glidant talc and 
compressed into tablets. Subliming agents was sublimed from the tablet by exposing it to drying 
at 60 
0
C. the tablets were evaluated for percentage friability, hardness, weight variation, 
disintegration time and percentage drug content. Menthol containing tablets resulted in rapid 
disintegration as compared with tablets containing ammonium bicarbonate and camphor. 
Pooja et al., (2010) Prepared and evaluate orodispersible tablets of Levocetrizine HCL to 
disintegrate in mouth (without the aid of water), to enhance the clinical effects and 
bioavailability through pre-gastric absorption. Orodispersible tablets were formulated using two 
technique, that is direct compression (containing superdisintegrant) and effervescent technique. 
Various formulation batches B1-B9 were prepared; all ingredients were passed through sieve no 
60, mixed and compressed. The compression of orodispersible tablets by direct compression 
using suuperdisintegrant, as compared to effervescent technique significantly affects the drug 
release rate and disintegration time. 
 
 
Avani R. Gosai et al., (2008) Developed orodispersible tablets of Ondansetron HCL, 
because of its application in emesis condition, fast onset of action and avoidance of water is 
highly desirable. Tablets were prepared by direct compression using sodium starch glycolate and 
croscarmellose as superdisintegrants, as the combination of these two agents gives better 
disintegration of the tablet. Microcrystalline cellulose was used as diluent and mannitol, mint 
flavor, sodium saccharine to enhance the organoleptic properties of tablets. The tablets were 
evaluated for weight variation, mechanical strength, in-vitro disintegration time, in-vivo 
disintegration time, wetting time and drug release characteristics. Hardness and friability data 
indicated good mechanical strength of tablets. Dissolution study revealed faster release rate of 
Ondansetron HCL from the tablets as compared to pure drug and marketed conventional tablet 
formulation of Ondansetron hydrochloride. 
Radke R.S. et al., (2009) Have been prepared Orodispersible tablets of baclofen using 
various concentrations of superdisintegrant agents like Ac-Di-Sol, crospovidone, sodium starch 
glycolate by direct compression method. Nine formulations having superdisintegrants at different 
concentration levels were prepared. These tablets were evaluated for drug content, weight 
variation, friability, hardness, wetting time and in-vitro disintegration time. The 
superdisintegrants addition technique is a useful method for preparing orodispersible tablets by 
direct compression method. 
M. Kruthi et al., (2012) Developed taste masked orodispersible tablets of Drotaverine 
HCL. Taste masking is means of masking the bitter taste of drug for the improvement of 
palatability of the drug. Drotaverine HCL drug is a highly potent spasmolytic agent. These drug 
is capable for relieving the spasms of various organs, but it is a very bitter drug and slightly 
soluble in water. Formulate and evaluate orodispersible tablets of Drotaverine HCL, highly bitter 
drug, in which its bitter taste can be masked. Solid dispersion technique such as melt granulation 
and kneading method are used to mask the taste of the drug. The carriers like Glyceryl Behenate 
(Compritol 888 ATO), Glyceryl pamito sterate (precirol ATO 5) and sucrose fatty acid ester (D 
1811) are used to mask the bitterness of the drug by solid dispersion technique and these 
dispersion will be formulated further using super disintegrates. 
Sharma Deepak et al., (2012) Review on taste masking technologies for the drug. 
Acceptability of any dosage form are mainly depends over its taste i.e. mouth feel. Drug 
molecule interacts with taste receptor on the tongue to give bitter, sweet or salty taste sensation, 
 
 
when they dissolve in saliva. In market, there are numbers of pharmaceutical preparations 
available in which actives in bitter taste. The improved palatability in these products has 
prompted the development of numerous forfulations, which improved performance and 
acceptability. These techniques are not only mask the bitter taste of drug but also enhance the 
bioavailability and performance of drug dosage form. It includes adding sugars, flavors, 
sweeteners, use of lipoproteins, numbing taste buds, granulation, use of adsorbates, coating of 
drug, microencapsulation, multiple emulsion, viscosity modifier, vesicles and liposomes, prodrug 
and salt formation, inclusion and molecular complex, solid dispersion and Ion Exchange Resins 
(IERs) which have been tried by the formulators to mask the unpleasant taste of the bitter drugs. 
Tejash Serasiya et al., (2009) Design and optimization of orodispersible tablets of 
Pheniramine maleate were prepared by direct compression method using various 
superdisintegrants like crospovidone, croscarmellose, sodium starch glycolate, low substituted 
hydroxypropyl cellulose, pregelatinized starch. The prepared tablets were evaluated for 
uniformity of weight, hardness, friability, wetting time in-vitro disintegration time, in-vitro 
dispersion time and drug release study.  The concentration of superdisintegrants had an effect on 
disintegration time and in-vitro drug dissolution whereas hardness and friability of resulting 
tablets were founds to be independent of disintegrant concentration. The two formulations, one 
containing 10% of crospovidone and second containing 10% of croscarmellose sodium were 
found to give the best result. 
P.V. Swamy et al., (2010) Designed cost effective orodispersible tablets of 
Diethylcarbamazine Citrate. The Diethylcarbamazine Citrate an anthelmintic for improving 
patients compliance, especially, those of pediatric and geriatric categories with difficulty in 
swallowing, with the prime objective of arriving at cost effective product by effervescent 
method. In the effervescent method mixture of sodium bicarbonate and tartaric acid along with 
treated agar were used as disintegrants. 
Ramesh veeraveni et al., (2011) Developed orodispersible tablets of Valdecoxib, to 
disintegrate rapidly in the oral cavity upon contact with saliva by formation of easy to swallow 
suspension without the aid of water were prepared. Mass extrusion technique and sublimation 
methods were employed in designing of orodispersible formulations. In the study, bitter taste of 
valdecoxib was masked by using previously optimized ratio of Valdecoxib : Eudragit E-100. 
Orodispersible tablets were developed using the prepared taste masking granules and a mixture 
 
 
of excipients consisting of MCC and L-HPC by mass extrusion technique. Sublimation method 
also employed to formulate orodispersible tablets using camphor as subliming material and water 
soluble materials like mannitol. 
Paramita Dey et al., (2012) Review on orodispersible tablets, a new trend in drug 
delivery. The most common and preferred route of drug administration is through the oral route. 
Orodispersible tablets are gaining importance among novel oral drug delivery system as they 
have improved patients compliance and have some additional advantages compared to other oral 
formulation. They are also solid unit dosage forms, which disintegrate in the mouth within a 
minute in the presence of saliva due to super disintegrants in the formulation. Thus this type drug 
delivery helps a proper peroral administration in pediatric and geriatric population where 
swallowing is a matter of trouble. 
Monica R P Rao et al., (2010) Designed and developed immediate release tablets of 
Metoclopramide HCL using simplex centroid mixture design. Metoclopramide HCL is mainly 
used as an anti-emetic agent in the cancer chemotherapy. Immediate release tablet formulations 
is based on the use of super disintegrants separately or in combination. Seven formulations were 
prepared by using simplex centroid mixture design where sodium starch glycolate (X1), cross 
carmellose sodium (X2), pregelatinised starch (X3) were selected as independent variables and 
dependent variables were disintegration time (Y1), and release at 15 minutes (Y2). Optimum 
formulation were selected by grid search method. X1, X2 andX3 when used individually gave 
satisfactory results but when used in combination gave better results. The results showed a good 
relationship between the experimental and predicted values. 
Rajesh Roshan Rai et al., (2012) Fast dissolving tablets a novel approach to drug 
delivery. Oral delivery is currently the gold standard in the pharmaceutical industry where it is 
regarded as thesafest, most convenient and most economical method of the drug delivery having 
the highest patient compliance. Yet, dysphagia is a common problem encountered in all age 
groups in concern to solid dosage forms. To overcome such problems, certain innovative drug 
delivery systems, like fast dissolving tablets (FDT) have been developed. Fast dissolving tablets 
have received ever- increasing demand during the last decade and the field has become a rapidly 
growing area in the pharmaceutical industry. 
Supriya Shidhaye et al., (2009) Developed novel melt granulation using sugars for 
Metoclopramide HCL orally disintegrating tablet. The taste masking of Metoclopramide HCL 
 
 
was carried out by forming complex with indion 244 using batch process. Further this complex 
was formulated into ODT using melt granulation technique. A blend of low melting and high 
melting sugar was used in this technique. 
Mathew Ebin P Sovichan et al., (2012) Developed Amoxicillin Trihydrate dispersible 
tablets in a low production value, using cheap amoxicillin trihydrate raw materials available in 
the market, with direct compression or wet granulation. Amoxicillin trihydrate is a semisynthetic 
antibiotic, an analogue of ampicillin with a broad spectrum of bactericidal activity against gram 
positive and gram negative organism. Amoxicillin trihydrate dispersible tablets was 
manufactured with the different disintegrants such as maize starch, crospovidone, 
croscarmellose, sodium starch glycolate. And then tablets are evaluate, the wet granulation was 
excluded from the formulation due to its high cost of production, direct compression was 
selected due to its low cost and easy of production. 
Amrutkar et al., (2010) Designed chewable dispersible tablet of Lamotrigine by melt 
granulation. Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is chemically 
unrelated to existing antiepileptic drugs. But it is a bitter drug and slightly soluble in water. Thus, 
in the work under taken, an attempt was made to mask the taste and to formulate into a chewable 
dispersible tablet by complexation with precirol ATO-05 ratio of 1:2, 1:1.5, 1:1, 1:0.5. the 
prepared tablets were then evaluated for general appearance, content uniformity, hardness, 
friability, taste evaluation, mouth feel, in-vitro disintegration time and in-vitro dissolution 
studies. Tablets with preciol ATO-05 have shown good disintegrating features, also, the 
dispersion not showing any bitter taste. 
Srinivasa Rao et al., (2011) Developed fast dissolving tablets of taste masked 
Ondansetron HCL. The Ondansetron HCL is a selective inhibitor of type-3 serotonium (5-HT 3) 
receptor, is an antiemetic. It is an intensely bitter in taste. In this investigation an attempt has 
been made to prepare bitter less fast dissolving tablet of Ondansetron HCL using Eudragit E 100 
as a taste masking agent. Mass extrusion was the technique used for preparing the taste masked 
granules. Drug polymer complexes were tested for drug content, in-vitro taste evaluation in 
simulated salivery fluid (SSF) of pH 6.2  and drug excipient interaction (IR Spectroscopy). 
Complex that did not release drug in SSF was considered taste masked and selected for 
formulation of fast dissolving tablets. 
 
 
Adel M. Aly et al., (2011) Prepared and evaluate rapidly disintegrating tablets of 
Glimepiride by direct compression, and also evaluate Pharmaburst as a newly introduced diluent 
for this type of tablets, either alone or in combination with other well-known tablet excipients. 
Orange flavor was the most preferred flavor for the prepared rapidly disintegrating tablets 
containing pharmaburst as a single diluent. The prepared Glimepiride RDT were found to have 
faster onset of action than the conventional  Glimepiride tablets. 
Rajesh M. et al., (2012) Developed taste masked Cefuroxime Axetil tablet by direct 
compression method. This study was aimed to formulate dispersible tablets in pediatric strength 
and to overcome the drawbacks of conventional Cefuroxime Axetil tablets such as swallowing 
difficulty and bitter taste. Taste masking was done by adopting four taste masking methods 
including Addition of flavors and sweetener, Granulation with stearic acid by slugging process, 
polymer coating method and inclusion complexation with β-cyclodextrin. Seven formulations 
were prepared by above four taste masking methods and various pre-compression parameters 
like angle of repose, bulk density, tapped density, compressibility index, hausners ratio and post 
compression parameters like appearance, thickness, hardness, weight variation, friability, 
disintegration time, drug content, wetting time, water absorption ratio, fineness of dispersion, in-
vitro drug release and taste evaluation were studied. The formulation prepared by using inclusion 
complexation taste masking method was considered as optimized formulation.  
 
 
 
 
 
  
 
 
 
 
 
 
3. AIM AND OBJECTIVE 
NEED AND SCOPE OF THE STUDY: 
Tablets and capsules are most papular solid dosage forms. However, many people face 
difficulty in swallowing tablets and hard gelatin capsules. This difficulty in swallowing is called 
as dysphasia. This problem has been encountered in all groups of patients, but especially with 
pediatric and geriatric populations. Thus, these conventional dosage forms result in high 
incidence of noncompliance and ineffective therapy with respect to swallowing specially in the 
case of pediatric, geriatric, or any mentally retarded persons. An Orodispersible tablet of 
metoclopramide hydrochloride is developed by direct compression techniques which disintegrate 
in oral cavity without the need of water within a matter of seconds when placed upon the tongue. 
“Orodispersible tablet are not only indicated for people who have swallowing difficulties, but 
also ideal for active people.” Hence, to resolve these problems the present work is aimed to 
develop and evaluate orodispersible tablets of metoclopramide hydrochloride using different 
superdisintegrants. 
The aim of study is to develop and evaluate the orodispersible tablets of metoclopramide Hcl. 
     To improve patient compliance. 
     To develop cost effective product. 
     To enhanced the onset of action of metoclopramide Hcl. 
     To enhance the safety and efficacy of metoclopramide Hcl. 
                     The main aim of the present study is to develop orodispersible tablets of 
metoclopramide hydrochloride (an antiemetic) for improving patient compliance, especially 
those of pediatric and geriatric categories with difficulty in swallowing, nausea and vomiting 
with prime objective of arriving at cost effective product, by direct compression techniques. 
 The objective is to increase the release rate of dissolution by increase the release 
rate of drug from the solid oral dosage form by using different superdisintegrants. 
 In the present work, metoclopramide hydrochloride is chosen as a model drug. 
Metoclopramide hydrochloride is a prokinetic drugs. It is chemically 4 - amino - 5 - chloro - N - 
(2 - (diethylamino) ethyl) - 2 - methoxy benzamide monohydrochloride monohydrate. It is an 
 
 
effective antiemetic. Metoclopramide hydrochloride is rapidly absorbed from orally its oral 
bioavailability is 80% and half-life is 5-6 hrs. Metoclopramide hydrochloride is a dopamine 
antagonist, it blocks D2 receptors in the CTZ. And shows the antiemetic action. On high dose it 
shows a 5-HT3 receptor antagonist. It is also used to treat gastroesophageal reflux disease 
(GERD). The dose of metoclopramide hydrochloride is 5 to 10mg for adults and 0.25 to 0.5mg 
for childrens t.i.d. orally. 
                            The objective of present work is to mask the taste of metoclopramide 
hydrochloride by using flavours and sweetners. And to develop the orodispersible tablets by 
simple and cost effective methods. The scope of this orodispersible drug delivery system is 
suitable for patients who suffering from dysphasia, nausea and vomiting, bedridden. And in the 
present work we have find out the comparative dissolution and disintegration study between our 
tablet formulation of metoclopramide hydrochloride orodispersible tablet. 
 
OBJECTIVES OF THE STUDY: 
 
1. To prepare ODT of metoclopramide Hcl. by direct compression using different concentration 
of superdisintegrants like crospovidone (polyplasdone), croscarmellose sodium (Ac-Di-Sol), 
and sodium starch glycolate (explotab). 
2. To evaluate the formulated tablets for various parameters, including stability study. 
3. To develop a dosage form which gives more rapid onset of action compared to oral 
conventional dosage form to improve patient compliance.  
 
 
 
 
 
 
 
 
 
 
 
4. PLAN OF WORK 
1. Literature survey.  
2. Procurement of drug,polymer and excipients. 
3. Preformulation studies. 
I) Identification and characterization of Metoclopramide Hcl.  
 Melting point. 
 Infrared absorption spectrophotometer. 
 Ultra visible spectrophotometer. 
 Identification test. 
 Solubility. 
II) Drug Excipient Interaction study by FTIR. 
III)  Development of standard calibration curve of Metoclopramide Hcl. 
 
4. Formulation Design. 
 Development of oro-dispersible tablet formulation using three different  
Superdisintegrating agent. 
 Preparation of powder blend of drug and excipients. 
5. Pre-compression assessment of powder blend. 
 Angle of repose. 
  Bulk density. 
 Tapped density. 
 Compressibility index. 
  Hausner ratio. 
6.Compression of powder blend into tablet by direct compression method. 
7. Post compression assessment of oro-dispersible tablet. 
 
 
  Hardness. 
  Friability. 
  Thickness. 
  Weight variation. 
  In-vitro dispersion time. 
  Wetting time. 
  Water absorption ratio. 
  Disintegration time. 
  Drug content. 
  In-vitro dissolution. 
8. Stability study. 
9. Comparison of Best Formulation with all batches. 
10. Result and discussion. 
11. Summary and conclusion.  
 
 
 
 
 
 
 
 
 
 
 
 
5. DRUG PROFILE 
METOCLOPRAMIDE HYDROCHLORIDE 
Molecular Formula   :C14H22ClN3O2.HCl.H2O 
Chemical Structure  :  
 
 
IUPAC Name  : 4-amino-5-chloro-N-[ 2-(diethylamino) ethyl]-
2methoxybenzamide  hydrochloride monohydrate. 
Brand Name             : Emetid, Imperan, Maxolon, Reclomide, Reglan. 
Drug Category            : Antiemetics,Dopamine Antagonists,Prokinetic Agents. 
Molecular Weight            :  354.3 
State               : solid 
Melting Point             : 182.5-184 
0
C 
Description              : A white or almost white, crystalline powder or crystals. 
Solubility                     : Very soluble in water, freely soluble in alcohol, sparingly            soluble 
in methylene chloride. 
Indication              : For the treatment of nausea and vomiting. 
Dose               : In adults 5-10 mg, in children 0.25-0.5 mg/kg tid. Orally. 
 
 
Bioavailability           : 80±15% (oral) 
Protein Binding            : 30% 
Half Life             : 5-6 hr 
Absorption             : Rapidly and well absorbed from orally 
Biotransformation           : Hepatic 
Excretion            :  70-85% renal, 2% faecal 
Pharmacology           :                
Metoclopramide hydrochloride, although chemically related to procainamide, does not 
possess local anesthetic or antiarrhythmic properties. Metoclopramide hydrochloride is used to 
enhance GI motility, to treat diabetic gastroparesis, as an antinauseant, and to facilitate intubation 
of the small bowel during radiologic examination. Metoclopramide hydrochloride may be used 
to treat chemotherapy induced emesis. 
Mechanism of Action : 
Metoclopramide hydrochloride inhibits gastric smooth muscle relaxation produced by 
dopamine, therefore increasing cholinergic response of the gastrointestinal smooth muscle. It 
appears to bind to dopamine D2 receptors where it is a receptor antagonist. The antiemetic action 
of metoclopramide hydrochloride is due to its antagonist activity at D2 receptors in the 
chemoreceptor trigger zone (CTZ) in the central nervous system this action prevents nausea and 
vomiting triggered by most stimuli. It accelerates intestinal transit and gastric emptying by 
preventing relaxation of gastric body and increasing the phasic activity of antrum. 
Simultaneously, this action is accompanied by relaxation of the upper small intestine, resulting in 
an improved coordination between the body and antrum of the stomach and upper small 
intestine. Metoclopramide hydrochloride also decreases reflux into the esophagus by increasing 
the resting pressure of the lower esophageal sphincter. 
Therapeutic Uses : 
 
 
Therapeutic indication are used to treat nausea and vomiting, it is effective and popular 
drug for many types of vomiting. Gastrokinetic: to accelerate gastric emptying, Dyspepsia, 
Gastroesophageal reflux disease (GERD). 
Adverse Effects : 
Common adverse drug reactions arerestlessness, drowsiness, dizziness, fatigue, and focal 
dystonia. Rare but serious adverse drug reactions are agranulocytosis, tardive dyskinesia. 
Contraindications : 
Metoclopramide hydrochloride is contraindicated in phaeochromocytoma, It should be 
used with caution in parkinson‟s disease. 
Drug Ineraction : 
Drug Interaction 
Cyclosporine Metoclopramide hydrochloride increases serum levels of 
cyclosporine.   
Levodopa Levodopa decreases the effect of metoclopramide 
hydrochloride. 
Paliperidone Metoclopramide hydrochloride may increase the risk of 
extrapyramidal side effects of paliperidone. 
Tacrolimus Metoclopramide hydrochloride may incerase the concentration 
of taccrolimus in the blood. 
Venlafaxine Possible serotoninergic syndrome with this combination. 
 
Food Interaction :        Food reduces availability, take 30 minutes before meals. Avoid alcohol. 
Storage :   Store protected from light and moisture. 
 
 
 
 
6. EXCIPIENTS PROFILE 
A) Croscarmellose sodium 
  
Nonproprietary Name        : USP-NF :Croscarmellose sodium. 
 
Synonyms            : Ac-Di-Sol, cross-linked carboxymethyl cellulose sodium,  
 
Chemical Name            : Cellulose, carboxymethyl ether, sodium salt, crosslinked. 
 
CAS RegestryNumber        : 74811-65-7. 
 
Molecular Weight            : 90000-700000. 
 
Functional Category           : Tablet and capsule disintegrant. 
 
Description  : Croscarmellose sodium occurs as an odorless, white or grayis
 white powder. 
 
Structural formula : 
 
 
 
pH                                         : 5.0-7.0 in aqueous dispersion. 
 
 
 
Specific Surface Area         : 0.81-0.83 m
2
/g.                  
 
Solubility                            : Insoluble in water. Although croscarmellose sodium rapidly swells 
to 4-8 times its original volume on contact with water. Practically 
insoluble in acetone and ethanol. 
Application: 
            Croscarmellose sodium is used in oral pharmaceutical formulation as a disintegrant for 
capsules, tablets and granules.In tablet formulation, croscarmellose sodium may be used in both 
direct compression and wet granulation processes.Whenused in wet granulations, the 
croscarmellose sodium should beadded in both the wet and dry stages of the processes (intra and 
exatra granulary) so that the wicking and swelling ability of the     disintegrant is best utilized. 
Croscarmellose sodium atconcentrations up to 5% w/w may be used as tablet disintegrant, 
although normally 2% w/w is used in tablet prepared by direct compression and 3% w/w in tablet 
prepared by a wet granulation process. 
Stability And Storage Condition: 
  Croscarmellos sodium is a stable though hygroscopic material. A model tablet 
formulation prepared by direct compression,with croscarmellose sodium as a disintegrant, 
showed no significant difference in drug dissolution after storage at 30
0
c for 14 months. 
Croscarmellose sodium should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
             The efficacy of disintegrants, such as croscarmellose sodium, may be slightly reduced in 
tablet formulations prepared by either the wet granulation or direct compression process that 
contain hygroscopic excipients such as sorbitol. 
Saftey: 
              Croscarmellose sodium is mainly used as a disintegrant in oral pharmaceutical 
formulation and is generally regarded as an essentially nontoxic and nonirritant material. 
However, oral consumption of large amounts of croscarmellose sodium may have a laxative 
effect, although the quantities used in solid dosage formulations are unlikely to cause such 
problems. 
 
 
 
B) Crospovidone 
 
Nonproprietary Name :     BP          : Crospovidone. 
 
                                             PhEur :     Crospovidonum. 
 
                                            USPNF :   Crospovidone. 
 
Synonyms   :   Croslinked povidone, kollidon CL, polyplasdone XL,  
                                         PVPP, polyvinyl polypyrrolidone. 
 
Chemical name  : 1-Ethenyl-2-polypyrrolidinone homopolymer. 
 
CAS Regestry Number              : 9003-39-8. 
 
Molecular Weight                   : >1 000 000. 
 
Functionly Category                   : Tablet disintegrant. 
Description                                  : Crospovidone is a white to creamy white, finely           
divided,free flowing, practically tasteless, odorlessor nearly 
odorless, hygroscopic powder. 
Structural Formula : 
 
 
 
 
pH   : 5.0-8.0 (1% w/v aqueous slurry). 
Density   : 1.22 g/cm
3
. 
Solubility   :         Practically insoluble in water and most common organic              
                                                            Solvents. 
Moisture Content  : Maximum miosture sorption is approximately 60%. 
Application : 
Crospovidone is a water insoluble tablet disintegrants and dissolution agent used at 2-5% 
concentration in tablet prepared by direct compression or wet and dry granulation methods. It 
rapidly exhibits high capillary activity and pronounced hydration capacity, with little tendency to 
form gels. Studies suggest that the particle size of crospovidone strongly influences 
disintegration of analgesic tablets. Larger particle provides afaster disintegration than smaller 
particles. Crospovidone can also be used as a solubility enhancer with the technique of co-
evaporation, crospovidone can be used to enhance the solubility of  poorly soluble drugs. The 
drug is adsorbed on to crospovidone in the presence of a suitable solvent and the solvent is then 
evaporated. This technique results in faster dissolution rate. 
Stability And Storage Condition : 
Since crospovidone is hygroscopic, it should be stored in  air tight container in a cool and 
dry place. 
Incompatibilities : 
Crospovidone is compatible with most organic and inorganic pharmaceutical ingredients. 
When exposed to a high water level, crospovidone may form molecular adducts with some 
materials. 
Safety : 
Crospovidone is used in oral pharmaceutical formulations and is  generally regarded as a 
nontoxic and nonirritant material. Short-term animal toxicity studies have shown no adverse 
effects associated with crospovidone. 
 
 
 
 
 
 
 
C) Sodium Starch Glycolate 
 
Nnonproprietary Name :                     BP : Sodium starch glycollate. 
 
                                                           PhEur : Carboxymethylamylum natricum. 
 
                                                           USPNF : Sodium starch glycolate. 
 
Synonyms        :  Carboxymethyl starch, Sodium salt, Explotab, Primojel. 
 
Chemical Name      :  Sodium carboxymethyl starch. 
 
CAS Regestry Number :  9063-38-1. 
 
Molecular Weight      : 5×10
5
-1×10
6
. 
 
Functional Category      : Tablet and capsule disintegrant. 
 
Description         : Sodium starch glycolate is a white to off-white, odorless,  
                                            tasteless, free-flowing powder. It consist of oval or           
                                            spherical granules 30-100µm in diameter. 
 
Structural Formula : 
 
 
 
 
 
pH               : 3.0-5.0. 
 
Melting Point              : Does not melt, but chars at approximately 200
0
C. 
 
Specific Surface Area           : 0.24 m
2
/g. 
Solubility                        :Sparingly soluble in ethanol (95%), practically insoluble in  water.     
 
Swelling Capacity  : In water, sodium starch glycolate swells to up to 300 time         
its volume. 
 
Application :             
Sodium starch glycolate is widely used in oral pharmaceuticale as a disintegrant in 
capsule and tablet formulations. It is commonly used in tablets prepared by either direct 
compression or wet granulation processes. The usual concentration employed in a formulation is 
between 2% and 8%, with the optimum concentration about 4%, although in many cases 2% is 
sufficient. Disintegration occurs by rapid uptake of water followed by rapid and enormous 
swelleing. 
 
Stability And Storage Condition : 
Tablets prepared with sodium starch glycolate have good storage properties. Sodium 
starch glycolate is stable and should be stored in a well closed container in order to protect it 
from wide variations of humidity and temperature, which may caues caking. 
 
Incompatibilities : 
                                          Sodium starch glycolate is incompatible with ascorbic acid. 
 
Safety : 
Sodium starch glycolate is widely used in oral pharmaceutical formulations and is 
generally regarded as a nontoxic and nonirritant material. However, oral ingestion of large 
quantities may be harmful. 
 
 
 
D) Microcrystalline Cellulose (MCC) 
 
Nonproprietary Name :                     BP :            Microcrystalline cellulose. 
 
                                                            PhEur :       Cellulosum microcrystallinum. 
 
                                                            USPNF : Microcrystalline cellulose. 
 
Synonyms       : Avicel PH, cellulose gel, emcocel, fibrocel, tabulose. 
Chemical Name      : Cellulose. 
CAS Regestry Number :  9004-34-6. 
Molecular Weight       : 36,000. 
Functional Category      :  Adsorbent, suspending agent, tablet and capsule diluent,  
tablet disintegrant. 
Description       : 
Microcrystalline cellulose is a purified, partially depolymerized cellulose that occurs as a 
white, odorless, tasteless, crystalline powder composed of porous particles. 
Structural Formula : 
 
 
 
 
 
 
 
 
Uses of microcrystalline cellulose : 
 
Use Cconcentration (%) 
Adorbent 20-90 
Antiadherent 5-20 
Capsule binder /diluent 20-90 
Tablet disintegrant 5-15 
Tablet binder /diluent 20-90 
 
Melting point  : Chars at 260-270
0
C. 
 
Moisture Content  : Less than 5% w/w. 
 
Specific Surface Area : 1.21-1.30 m
2
/g. 
 
Solubility   : Slightly soluble in 5% w/v sodium hydroxide solution, 
                                       practically insoluble in water. 
 
Application :                         
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet granulation and 
direct compression processes. In addtion to its use as a binder/diluent, microcrystalline cellulose 
also has some lubricant and disintegrant properties that make it useful in tableting. 
 
Stability And Storage Condition :                      
Microcrystalline cellulose is a stable though hygroscopic material. The bulk material 
should be stored in a well closed container in a cool, dry place. 
 
Incompatibilities  
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
 
 
E) Aspartame 
 
Nonproprietary Name :                        BP : Aspartame. 
 
                                                            PhEur : Aspartamum. 
 
                                                           USPNF : Aspartame. 
 
Synonyms       :Canderel, equal, nutrasweet, pal sweet tri-sweet. 
 
Chemical Name       :N-α-L-Aspartyl-L-phenylalanine 1-methyl ester. 
 
CAS Regestry Number : 22839-47-0. 
 
Moleculer Weight       : 294.31. 
 
Empirical Formula        : C14H18N2O5. 
 
Functional Category      :Sweetening agent. 
 
Description        : Aspartame occurs as an off white, almost odorless  
                                            Crystalline powder with an intensely sweet taste. 
Structural Formula : 
 
 
 
 
 
 
pH    :   4.5-6.0 (0.8% w/v in aqueous solution). 
 
Melting Point  : 246-247
0
C. 
 
Solubility  : Slightly slouble in ethanol (95%), sparingly slouble in water. 
Application :       
Aspartame is used as an intense sweetening agent in beverage products, food products, 
and table-top sweetners, and in pharmaceutical preparations including tablets, powder mixes, and 
vitamin preparations. It enhances flavor systems and can be used to mask some unpleasant taste 
characteristics, the approximate sweetening power is 180-200 times that of sucrose. Aspartame is 
metabolized in the body and consequently has some nutritive value: 1g provides approximately 4 
kcal. Therapeutically, aspartame has also been used in the treatment of sickle cell anemia. 
 
Stability And Storage Condition : 
Aspartame is stable in dry conditions. The bulk material should be stored in a well-closed 
container in a cool, dry place. 
 
Safety :   
Aspartame is widely used in oral pharmaceutical formulations, beverages, and food 
products as an intense sweetner and is generally regarded as a nontoxic material. The WHO has 
set an acceptable daily intake for aspartame at upto 40mg/kg body weight. 
 
 
 
 
 
 
 
 
 
 
 
 
F) Magnesium Stearate 
Nnonproprietary Name :                 BP           :  Magnesium Stearate. 
 
                                                            PhEur     :   Magnesii stearas. 
 
                                                            USPNF  :   Magnesium stearate. 
 
Synonyms       : Magnesium octadecanoate, octadecanoic acid, magnesium salt. 
 
Chemical Name      : Octadecanoic acid magnesium salt. 
 
CAS Regestry Number :  557-04-0. 
 
Empirical Formula      :  C36H70MgO4. 
 
Molecular Weight       :  591.34. 
 
Functional Category      : Tablet and capsule lubricant. 
  
Structural Formula       :  [CH3(CH2)16COO]2 Mg. 
 
Flowability       :  Poorly flowing, cohesive powder. 
 
Melting Point       : 126-130
0
C. 
Solubility        : Practically insoluble in ethanol, ethanol (95%), ether 
                                 and wter, slightly slouble in warm benzene and warm ethanol (95%). 
Specific Surface                                  
Area         :  1.6-14.8 m
2
/g.                                              
Description        :      
Magnesium stearate is a very fine, light white, percipitated or milled, impalpable powder 
of low bulk density, having a  faint odor of stearic acid and a characteristic taste. 
 
 
Application : 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations. 
It is primarily used as a lubricant in capsule and tablet manufacture at concentrations between 
0.25% and 5.0% w/w. It is also used in barrier creams. 
 
Stability And Storage Condition : 
Magnesium stearate is stable and should be stored in a well-closed container in a cool, 
dry place. 
 
Incompatibilities :  
Magnesium stearate is incompatible with strong acids, alkalis, and iron salts. Avoid 
mixing with strong oxidizing materials. 
 
Handling Precautions : 
Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Eye protection and gloves are recommended. Excessive inhalation of magnesium 
stearate dust may cause upper respiratory tract discomfort, coughing. It should be handled in a 
well-ventilaed environment. 
 
Safety : 
Magnesium stearate is widely used as a pharmaceutical excipient and is generally 
regarded as baing nontoxic following oarl administration. 
 
 
 
 
 
 
 
 
 
 
 
G) Talc 
 
Nonproprietary Name :                          BP : Purifide talc. 
 
                                                             PhEur : Talcum. 
 
                                                             USP   :    Talc. 
 
Synonyms                  : Altalc, magnesium calcium silicate, powdered talc, magsil star. 
 
Chemical Name         :Talc. 
 
CAS Registry Number : 14807-96-6. 
 
Empirical Formula       : Mg6(SiO5)4 (OH)4. 
 
Functional Category     : Anticaking agent, glidant, tablet and capsule diluent, tablet  
                                          and capsule lubricant. 
 
Description                    : Talc is very fine, white to grayish white, odorless,  
                                          impalpable, crystalline powder. It adheres radily to the  
                                          skin and is soft to the touch and free from grittiness. 
 
pH                                  : 7-10 for a 20% w/v aqueous dispersion. 
 
Moisture Ccontent       : Talc absorbs insignificant amounts of water at 250C and  
                                          relative humidities up to about 90%. 
 
Specific Surface Area  :  2.41-2.42 m
2
/g. 
 
Specific Gravity            :2.7-2.8. 
 
 
 
Solubility                       : Practically insoluble in acids and alkalis, organic solvents,  
                                          and water. 
 
Application : 
Talc was once widely used in oral solid dosage formulations as a lubricant and diluent. 
Talc is additionally used to clarify liquids and is also used in cosmetics and food products, 
mainly for its lubricant properties. 
 
Concentrations of talc to be used in various applications : 
 
Use Concentration (%) 
Dusting powder 90.0-99.0 
Glidant and lubrucant 1.0-10.0 
Tablet and capsule diluent 5.0-30.0 
 
Stability And Storage Condition : 
Talc is a stable material and may be sterilized by heating at 160
0
C for not less than 1 
hour. It may also be sterilized by exposure to ethylene oxide or gamma irradiation. Talc should 
be stored in a well-closed container in a cool, dry place. 
 
Incompatibilities         : Incompatible with quaternary ammonium compounds. 
Handling Precautions : 
Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Talc is irritant if inhaled. 
Safety : 
Talc is used mainly in tablet and capsule formulations. Talc is not absorbed systemically 
following oral ingestion and is therefore regarded as an essentially nontoxic material. 
 
 
 
H) Aerosil 
 
Nonproprietary Name :                         BP :                Colloidal anhydrous silica. 
 
                                                            PhEur :           Silica colloidalis anhydrica.  
 
                                                         USPNF :         Colloidal silicon dioxide. 
 
Synonyms                      : Cab-O-Sil, colloidal silica, fumed silica wacker HDK. 
 
Chemical Name            : Silica. 
 
CAS Regstry Number : 7631-86-9. 
 
Empirical Formula      : SiO2. 
 
Molecular Weight        : 60.08. 
 
Structural Formula     : SiO2. 
 
Functional Category   :  Adsorbent, anticaking agent, emulsion stabilizer, glidant,  
                                          tablet disintegrant, thermal stabilizer. 
 
Description                  : Aerosil is a submicroscopic fumed silica with a particle size  
                                        of about 15 nm. It is a light, loose, bluish-white-coloured,  
                                        odorless, tasteless, nongritty amorphous powder. 
 
pH                                 : 3.5-4.4 (4% w/v aqueous dispersion). 
 
Flowability                   : 35.52%. 
 
 
 
Refractive Index          : 1.46. 
 
Specific Gravity           : 2.2. 
 
Specific Surface Area  : 200-400 m
2
/g. 
Solubility :           
Practically insoluble in organic solvents, wter, and acids, except hydrofluoric acid, 
soluble in hot solutions of alkali hydroxide. Forms a colloidal dispersion with water. 
 
Application :                                     
Aerosil is widely used in pharmaceuticals, cosmetics, and food products, Its small 
particle size and large specific surface area give it desirable flow characteristics that are 
exploited to improve the flow properties of dry powders in a number of processes such as 
tableting. Aerosil is also used as a tablet disintegrant and as an adsorbent dispersing agent for 
liquids in powders. 
 
Stability And Storage Condition : 
Aerosil is hygroscopic but adsorbs large quantities of water without liquefying. Aerosil 
powder should be stored in a well-closed container. 
 
Incompatibilities :             
Incompatible with diethylstilbestrol preparations. 
 
Safety : 
Aerosil is widely used in oral and topical pharmaceutical products. And is generally 
regarded as an essentially nontoxic and nonirritant exipient. 
 
 
 
 
 
 
 
I) Mannitol 
 
Nonproprietary Name :                          BP :                 Mannitol. 
 
                                                             PhEur :            Mannitolum. 
 
                                                               USP :               Mannitol. 
 
Synonyms                           :  Cordycepic acid, manna sugar, pearlitol. 
 
Chemical Name                 :  D-Mannitol. 
 
CAS Regstry Number      : 69-65-8. 
 
Empirical Formula           : C6H14O6. 
 
Moleculer Weight              :182.17. 
 
Functional Category         : Diluent, diluent for lyphilized preparations, sweetening  
                                               agent, tablet and capsule diluent. 
 
Structural Formula           : 
 
 
 
 
Description                        : Mannitol occurs as a white, odorless crystalline powder, or  
                                              free-flowing granules. It has a sweet taste, approximately as  
                                              sweet as glucose and half as sweet as sucrose, and imparts a  
                                              cooling sensation in the mouth. 
Melting Point                    : 166-168
0
C. 
 
Specific Surface Area      : 0.37-0.39 m
2
/g. 
 
Solubility                           : Mannitol is soluble in alkalis, ethanol (95%), water. It is  
                                              practically insoluble in ether. 
 
Application :          
Mannitol is widely used in pharmaceutical formulations and food products. In 
pharmaceutical preparations it is primarily used as a diluent (10-90% w/w) in tablet 
formulations. Mannitol may be used in direct compression tablet applications, for which the 
granular and spray dried forms are available, or inwet granulations. Mannitol is commonly used 
as an excipient in the manufacture of chewable tablet formulations because of its negative heat of 
solution, sweetness, and mouth feel. 
 
Stability And Storage Condition : 
Mannitol is stable in the dry state and in aqueous solutions. Solutions may strilized by 
filtration or by autoclaving. The bulk material should be stored in a well-closed container in a 
cool, dry place. 
Incompatibilities :           
Mannitol solutions, 20% w/v  or stronger, may be salted out by potassium chloride or 
sodium chloride. Mannitol is incompatible with xylitol infusion and may form comlexes with 
some metals such as ammonium, copper, and iron. 
Safety :    
Mannitol is a naturally occuring sugar alcohol found in animals and plants, it is present in 
small quantities in almost all vegetables. Laxative effects may occur if mannitol is consumed 
orally in large quantities. 
 
 
7. MATERIALS AND METHODS 
7.1 MATERIALS 
The following materials like Drug, Excipients and Chemicals were used for the 
formulation and evaluation studies of ODTs. 
Table No. 7.1: List of materials and their suppliers. 
Sr. 
No. 
Materials Manufacturer and Supplier of 
Materials 
1 Metoclopramide HCL Vaikunth Chemicals Pvt. Ltd., Bharuch. 
2 Sodium Starch Glycolate Vijlak Pharma Ltd., Mumbai. 
3 Crospovidone BASF Ltd., Pharmaco Mumbai. 
4 Crosscarmellose Sodium Ascot Pharma Ltd., Mumbai. 
5 Microcrystalline Cellulose Westurn Pharma, Mumbai. 
6 Aspartame Sinosweet Co. Ltd, Jaingsu, China. 
7 Magnesium Stearate Westurn Pharma, Mumbai. 
8 Talc Westurn Pharma, Mumbai. 
9 Aerosil Degussa, Westurn Pharma, Mumbai. 
10 Pineapple Flavor Vital Flavors, Mumbai. 
11 Mannitol Pharmaco, Mumbai. 
12 Sodium Hydroxide Qualigens Fine Chemicals, Mumbai. 
13 Potassium dihydrogen 
Orthophosphate 
Qualigens Fine Chemicals, Mumbai. 
14 Hydrochloric Acid Fisher Scientific India Pvt. Ltd., Mumbai 
15 Potassium Chloride Qualigens Fine Chemicals, Mumbai. 
16 Potassium Bromide S.D. Fine Chemical Ltd, Mumbai. 
 
 
 
 
 
 
 
 
7.2 INSTRUMENTS USED 
Table No. 7.2: List of instruments and manufacturer. 
Sr. 
No. 
Instruments Manufacturer 
1 Digital Balance AX 200, Shimadzu, Japan. 
2 Melting Point Apparatus Scientific International SI-934, Delhi. 
3 Double Beam                          
UV- Spectrophotometer 
Analytical technologies Ltd., Model No. 
2080 
4 Digital pH Meter Equip-Tronics, Model EQ 610. 
5 FTIR Spectrophotometer Model No. 8400 S, Shimadzu, Japan 
6 Tablet Compression Machine Cadmach Machinery co. Pvt. Ltd., 
Ahmadabad. 
7 Roche Friabilator Scientific International, New Delhi. 
8 Tablet Hardness Tester Monsanto Hardness Tester, Magumps, 
Bombay. 
9 Disintegration Apparatus ED-2L Electrolab, Mumbai. 
10 Dissolution Test Apparatus II USPXXIII, (TDT-08L) Plus, Electrolab, 
India. 
11 Vernier Caliper Mitutoyo Digital Vernier Caliper, Japan. 
 
7.3 METHODOLOGY 
7.3.1 Preformulation Study 
Identification of drug 
B) Melting Point : 
  Melting point of pure Metoclopramide HCL was determined by open capillary method. 
The capillary tube was closed at one end by fusion and was filled with Metoclopramide HCL by 
 
 
repeated tapings. The capillary tube was placed in a digital melting point apparatus. The 
instrument was set to automatically increase the temperature of heating bath at a rate 100
0
C min 
rise of temperature per minute. The rise in temperature was viewed through magnifying lens. The 
temperature at which the drug started melting was recorded. 
B)  Infrared absorption spectrophotometer : 
Identification of Metoclopramide HCL was determined by the infrared absorption 
spectrophotometer. The sample was heated in hot air oven for removing moisture content. The 
sample were prepared with potassium bromide by mixing it in mortar and pestle. The prepared 
sample was placed in FT-IR and scanned at range from 400 to 4000 cm
-1
 to obtain the spectrum. 
Theobtained spectrum was compared with the reference standard IR spectrum of 
metoclopramide HCL. 
C)  Ultra visible spectrophotometer : 
A solution of Metoclopramide HCL containing concentration 50µg/ml was prepared in 
water and the solution was scanned in the range of 200-400nm. The obtained spectrum was 
compared with the reference standard UV spectrum of metoclopramide HCL. 
D)  Identification test :  
Identification of metoclopramide HCL was determined by the chemical test for primary 
aromatic amines. Dissolve the drug about 2 mg in 2 ml of water the solution gives the reaction of 
primary amines (IP). 
E)  Solubility : 
Solubility of Metoclopramide hydrochloride was performed in solvents water and 
alcohol. 
7.3.2 Standard Calibration Curve of Metoclopramide HCL 
Preparation of stock solution of Metoclopramide HCL 
Weigh accurately 10 mg of Metoclopramide HCL and dissolve it in 100 ml of dilution 
media pH 6.8 buffer to obtain the stock solution of strength 100 µg/ml. and the respective 
dilutions were prepared by using stock solution. Same procedure was repeated for stock solution 
of metoclopramide HCL using pH 1.2 buffer as a dilution media. 
Calibration curve of Metoclopramide HCL in pH 1.2 buffer 
Procedure: 
 
 
                  10 mg of Metoclopramide HCL was dissolved in 100 ml of the pH 1.2 buffer to 
obtain the working standard of 100 µg/ml. Aliquots of 0.2 ml to 1 ml from the stock solution 
representing 2 to 10 µg/ml of drug were transferred to 10 ml volumetric flask and the volume 
was adjusted to 10 ml with the pH 1.2 buffer. Absorbance of the above solutions was measured 
at 273 nm. by UV visible spectrophotometer against the blank solution prepared in the same 
manner without adding the drug. A graph of absorbance Vs concentration was plotted and was 
found to be linear over a range of 2 to 10 µg/ml indicating its compliance with Beer‟s law. 
Calibration curve of Metoclopramide HCL in pH 6.8 buffer 
Procedure:  
      10 mg of Metoclopramide HCL was dissolved in 100 ml of the pH 6.8 buffer to 
obtain the working standard of 100 µg/ml. Aliquots of 0.2ml to 1ml from the stock solution 
representing 2 to 10 µg/ml of drug were transferred to 10 ml volumetric flask and the volume 
was adjusted to 10 ml with the pH 6.8 buffer. Absorbance of the above solutions was measured 
at 273 nm. by UV visible spectrophotometer against the blank solution prepared in the same 
manner without adding the drug. A graph of absorbance Vs concentration was plotted and was 
found to be linear over a range of 2 to 10 µg/ml indicating its compliance with Beer‟s law. 
Preparation of Buffer and Reagents 
The reagents were prepared as per I.P. 
Sodium Hydroxide (0.2M) solution :  
Eight gram of sodium hydroxide (NAOH) was dissolved in 1000 ml volumetric flask 
containing about 700 ml of distilled water and volume was made up to the mark with distilled 
water. 
Potassium Dihydrogen Phosphate (0.2M) solution : 
Potassium dihydrogen phosphate (27.218g) was dissolved in 1000 ml volumetric flask 
containing about 700 ml of distilled water and volume was made up to the mark with distilled 
water. 
Phosphate Buffer (pH 6.8) solution : 
                     Fifty ml of 0.2 M Potassium dihydrogen phosphate solution was taken in a 200 ml 
volumetric flask, to which 22.4 ml of 0.2 M sodium hydroxide solution was added and volume 
was made up to the 200 ml with distilled water. The pH was adjusted to 6.8 with dilute sodium 
hydroxide solution. 
 
 
0.2M Hydrochloric acid (HCL) solution:  
Conc. HCl diluted with distilled water so that final solution contains 7.292 g of 
hydrochloric acid in 1000.0 ml to obtain 0.2M hydrochloric acid solution. 
0.2M Potassium chloride (KCL) solution:  
Dissolve approx. 14.911 g of potassium chloride in distilled water and diluted to 1000.0 
ml with distilled water to obtain 0.2M potassium chloride solution. 
pH 1.2 Hydrochloric acid buffer:  
About 250.0 ml of 0.2M potassium chloride solution was placed in a 1000.0 ml 
volumetric flask. To this, about 425.0 ml of 0.2M hydrochloric acid was added and then volume 
was adjusted to 1000 ml with distilled water. Then prepared solution was tested using pH meter. 
The pH of solution was adjusted to pH 1.2 with the help of 0.2M hydrochloric acid. 
7.3.3 Drug and Excipients Interaction Study 
FTIR Spectroscopy :  
The interaction between drug and excipients was studied by using FTIR spectroscopy. In 
the preparation of tablet formulation, drug and excipients may interact as they are in close 
contact with each other, which could lead to the instability of drug. Preformulation studies 
regarding the drug-excipients interaction are therefore very critical in selecting appropriate 
polymer. FTIR spectroscopy was employed to ascertain the compatibility between 
Metoclopramide hydrochloride and the selected excipients. Potassium bromide, pure drug and 
the excipients were heated to 105
0
C for one hour in a hot air oven to remove the moisture 
content. Then in presence of IR lamp, potassium bromide was mixed with drug and or excipients 
and the spectra were taken. FTIR spectrum of metoclopramide hydrochloride was compared with 
FTIR spectra of excipients. 
7.4 Formulation Development 
Selection of Superdisintegrants : 
The best type of superdisintegrants are incorporated in the formulation of ODTs like, 
Sodium starch glycolate, Crospovidone, Cross carmellose sodium. Before the tablet formulation 
the superdisintegrants was screened out and taken into formulation with other excipients for 
compression by direct compression method. The superdisintegrant shows good properties like, 
when the tablet comes in contact with liquid, it breaks up into smaller particles because of 
 
 
superdisintegrants are swells, hydrate, change the volume and produce a disruptive change in the 
tablet. 
            In this work, the direct compression method with aid of superdisintegrants was attempted 
for the formulation development of orodispersible tablets of Metoclopramide hydrochloride. The 
superdisintegrants like Sodium starch glycolate, Crospovidone, Cross carmellose sodium were 
taken for the formulation development. The Metoclopramide hydrochloride tablets are available 
in 5mg and 10mg doses in the market. Dose of 10mg is selected for the present study. 
The development of the formulation of orodispersible tablets in the present study was 
mainly based on the type and concentration of superdisintegrants. Various superdisintegrants in 
different concentrations (2.6%, 4%, and 5.3%) were used so as to get tablets with good physical 
properties. Ingredients like Microcrystalline cellulose and mannitol as directly compressible 
diluents, magnesium stearate and talc as lubricant, aerosil as flow promoter, aspartame as 
sweetening agent and pineapple flavor as enhance the palatability. And Sodium Starch Glycolate 
(Carboxtmethyl Starch), Crospovidone (Polyplasdone XL) and Cross Carmellose Sodium (Ac-
Di-Sol) were taken in the different concentrations such as 2.6%, 4%, and 5.3%.  
          The formulation design of orodispersible tablets of Metoclopramide HCL is shown in 
Table 7.3. 
Table No. 7.3: Formulation design of Metoclopramide HCL orodispersible tablets. 
Sr
. 
N
o. 
Ingredients (mg) MF1 MF2 MF3 MF4 MF5 MF6 MF7 MF8 MF9 
1. Metoclopramide 
HCL 
10 10 10 10 10 10 10 10 10 
2. Sodium starch 
glycolate 
4 6 8 _ _ _ _ _ _ 
3. Crospovidone _ _ _ 4 6 8 _ _ _ 
4. Cross carmellose 
sodium 
_ _ _ _ _ _ 4 6 8 
5. Microcrystalline 
cellulose 
50 50 50 50 50 50 50 50 50 
6. Aspartame 6 6 6 6 6 6 6 6 6 
 
 
7. Magnesium 
stearate 
1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
8. Talc 1 1 1 1 1 1 1 1 1 
9. Aerosil 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
10 Pineapple flavour 1 1 1 1 1 1 1 1 1 
11 Mannitol 76 74 72 76 74 72 76 74 72 
 Total 150 150 150 150 150 150 150 150 150 
Tablets were prepared in batch of 100  
             Metoclopramide HCL orodispersible tablets were prepared by direct compression 
method. The ingredients mentioned in table 7.3 were used for formulation such as, 
superdisintegrants in different concentration, Microcrystalline cellulose as diluent, mannitol as 
directly compressible diluent, aspartame was selected as sweetening agent due to its intense 
sweetness, magnesium stearate and talc as lubricant, aerosil as flow promoter and flavor 
(Pineapple flavor) was added it enhance the palatability of tablets. 
Preparation of powder blend of drug and excipients : 
The powder blend for orodispersible tablets were prepared by taking ingredients given in 
Table 7.3 
            All the ingredients were passed through 60 mesh sieve separately and collected. Then 
ingredients were weighed and mixed in a geometrical order. First Microcrystalline cellulose, 
Mannitol and Superdisintegrants were weighed and mixed together in glass mortar using a pestle. 
Then Drug and Aspartame were mixed and added in first mixer. Then Magnesium stearate, Talc 
and Aerosil were added and mixed. Finally flavor (Pineapple flavor) was added and mixed for 
10-20 minutes. 
             Before tablets preparation, the mixture blends of all the formulations were subjected for 
compatibility studies (IR) and pre-compression parameter like Angle of repose, Bulk density, 
Tapped density, Percentage compressibility and Hausner ratio. 
Preparation of Metoclopramide HCL Orodispersible Tablets by Direct Compression : 
Metoclopramide HCL orodispersible tablets were prepared in nine formulations MF1 to 
MF9 using the ingredients given in the Table 7.3 keeping the total weight of the tablet (150mg) 
kept constant in all the formulations. All the ingredients were passed through 60 mesh sieve 
separately and collected. Then ingredients were weighed and mixed in a geometrical order. First 
 
 
microcrystalline cellulose, mannitol and superdisintegrants were weighed and mixed together in 
glass mortar using a pestle. Then drug and aspartame were mixed and added in first mixer. The 
blend was then lubricated by mixing with magnesium stearate, talc and aerosil. Finally the 
mixture was blended with flavor. Then the powder blend was compressed. Tablets were prepared 
using 8 mm round flat-faced punches of the 16-station (Cadmach Machineries ltd.) rotary tablet 
compression machine. Compression force was kept constant for all formulation. 
          The Orodispersible tablets were prepared and subjected to post compression parameters 
likehardness, friability, thickness, weight variation,In-vitro dispersion time, wetting time, water 
absorption ratio, drug content, In-vitro disintegration time and In-vitro dissolution. 
7.5 Pre-compression assessment of powder blend 
          Different parameters were evaluated for prepared powder blend using following methods. 
Angle of repose 
Angle of repose is defined as maximum angle possible between the surface of the pile of 
powder and the horizontal plane. 
           The friction force in a loose powder can be measured by the angle of repose (θ). It is an 
indicative of the flow properties of the powder. 
The angle of repose is calculated by using fixed funnel method. In this method the funnel 
was fixed to a stand at definite height (h). The graph paper was placed on a flat horizontal 
surface. Then powder blend was allowed to fall freely on the paper through the funnel, until the 
apex of the conical pile just touches the tip of the funnel. The height and radius of pile was noted 
and from this angle of repose was determined with the help of given formula. 
The formula for calculating angle of repose is – tan (θ) = h / r 
                                                                             θ= tan-1 (h / r) 
                           Where, 
                                    θ   is the angle of repose 
                                    h   is the height in cm. 
                                    r is the radius in cm. 
 
 
 
 
 
 
Table No. 7.4: Angle of repose as an indication of powder flow properties: 
Sr. No. Angle of Repose (°) Type of Flow 
1 <20 Excellent 
2 20-30 Good 
3 30-34 Passable 
4 >34 Very poor 
 
Bulk Density 
  Bulk density is the ratio of total mass of powder to the bulk volume of powder. It was 
measured by pouring the accurately weighed 2g of powder blend (passed through 20 mesh sieve) 
was placed in a 10ml graduated measuring cylinder. And then initial volume was observed, this 
initial volume is called as bulk volume. From this the bulk density was calculated by using the 
following formula. 
                    Db = M / Vb 
                            Where,       Db = Bulk density. 
                                              M= Mass of the powder.  
                                              Vb= Bulk volume of the powder. 
Tapped Density 
Tapped density is the ratio of total mass of powder to the tapped volume of powder. 
Accurately weighed amount of powder blend was placed in a measuring cylinder and the volume 
was measured by tapping of powder for 500 times and the tapped volume was noted. The tapped 
density was calculated by using following formula. 
                                 Dt= M / Vt 
                                     Where,       Dt = Tapped density. 
                                                       M = Mass of the powder. 
                                                       Vt = Tapped volume of the powder. 
Compressibility Index 
Compressibility index is indicates the powder flow properties. It is expressed in 
percentage. Compressibility index is based on the bulk density and tapped density, the 
percentage compressibility of the powder blend was determined by using the following formula. 
 
 
          Dt - Db 
I = 
____________
 × 100 
             Dt 
Where,  
                    I = Compressibility index. 
                    Dt = Tapped density of the powder. 
                    Db = Bulk density of the powder. 
Table No. 7.5: Relationship between % compressibility and flow ability. 
% Compressibility Flow ability 
5 – 12 Excellent 
12 – 16 Good 
18 – 21 Fair passable 
23 – 35 Poor 
33 – 38 Very poor 
 
Hausner Ratio 
          Hausner ratio is an indirect index of ease of powder flow. It was calculated by the 
following formula.  
                  Hausner ratio = Dt / Db 
                              Where, 
                                       Dt = tapped density. 
                                       Db = bulk density. 
 Lower Hausner ratio (< 1.25) indicates better flow properties than higher 
ones (> 1.25). 
7.6 Post-compression assessment of powder blend 
Hardness 
Hardness of the tablet was determined by using Monsanto tablet hardness tester. 
Hardness or tablet crushing strength (fc), the force required to break a tablet in a diametric 
compression. From each batch, hardness of 6 tablets was determined. The lower plunger is 
placed in contact with tablet, and a zero reading was taken. The upper plunger is then forced 
 
 
against a spring by turning a threaded bolt until the tablet fractures. Hardness of tablet is 
expressed in kg / cm
2
. 
Friability 
The friability test for tablets was performed to assess the effect of abrasion and shocks. 
Roche friabilator was used for the percent friability of the tablets. This device subjects the tablet 
to the combined effect of abrasion and shock in a plastic chamber revolving at 25 rpm and 
dropping a tablet at a height of 6 inches in each revolution. Pre-weighted sample of tablets was 
placed in the friabilator and were subjected to the 100 revolutions. Then the tablets were 
removed and de dusted by using a soft muslin cloth and reweighed. The weight lost should not 
exceed the limit 1.0%. The percentage friability was measured by using the following formula. 
                W initial – W final 
% F = ---------------------------- × 100 
                       W initial 
          
          Where, 
                 % F = Friability in percentage. 
                W initial = Initial weight of tablet. 
                W final = Final weight of tablet. 
Thickness 
The thickness of tablets was measured by using vernier caliper. Five tablets from each 
batch were taken randomly and thickness was measured and average values were calculated. 
Thickness is expressed in mm. 
 
Weight Variation 
The weight variation test was performed as per I.P. Twenty tablets were randomly 
selected from each batch and individually weighed. And then average weight was calculated 
from the total weight of all tablets. The individual weights were compared with the average 
weight.The tablets passes the test for weight variation test if no more than two tablets are outside 
the percentage limit and if no tablet differs by more than two times the percentage limit. Weight 
variation specification as per I.P. is shown in Table no. 7.6. 
 
 
 
Table No. 7.6: Weight variation tolerances for uncoated tablets. 
Average weight of tablets (mg) % Deviation 
80 mg or less ±10 
More than 80 mg and less than 250 
mg 
±7.5 
250 mg or more ±5 
 
In-vitro Dispersion Time 
In-vitro dispersion time was measured by dropping a tablet into a petridish containing 
10ml of phosphate buffer pH 6.8 solution at 37± 0.5
0
c. Three tablets from each batch were 
randomly selected and tested the time required for complete dispersion of a tablet was measured. 
The in-vitro dispersion time is expressed in seconds. 
Wetting Time 
            A piece of tissue paper folded double was placed in a Petri dish (6.5cm) containing 6 ml 
of water .the tablet was placed on the paper, and the time for complete wetting of the tablet was 
measured in seconds. The method was slightly modified by maintaining water at 37
0
c.Wetting 
time corresponding to the time taken for the tablet to disintegrate when kept motionless on the 
Petri dish. 
Water Absorption Ratio 
             A piece of tissue paper folded twice was placed in a petri dish (6.5cm) containing 6 ml 
of water. A tablet was put on the tissue paper and the time required for the complete wetting was 
measured. The wetted tablet was then weighed. Water absorption ratio, R, was determined using 
following equation. 
            R = 100 (Wa-Wb) / Wb 
                   Where,             
                           Wa = Weight of the tablet after absorption. 
                           Wb = Weight of the tablet before absorption. 
 
 
 
Figure No. 7.1: Method for measurement of wetting time and water absorption ratio. 
 
Disintegration Time 
             The in-vitro disintegration time of a tablet was determined using disintegration test 
apparatus. One tablet was placed in each of the six tubes of the apparatus and one disc was added 
to each tube and run the apparatus using distilled water at 37
0
c ± 2
0
c. And then complete 
disintegration of tablet with no palpable mass remaining in the apparatus was measured in 
seconds. 
Drug Content 
            The drug content of the tablets was measured according to the procedure given in IP, 
2007. It has been reported that metoclopramide HCl can be detected at 273 & 305 nm. Drug 
content uniformity was carried out at 305 nm because successive extraction was done using 
chloroform for which maximum absorption observed at 305 nm as reported in pharmacopoeia. 
In-vitro Dissolution Studies 
                  In-vitro dissolution studies for orodispersible tablets of Metoclopramide HCL were 
carried out using USP apparatus type II at 50 rpm. The dissolution medium used was phosphate 
buffer pH 6.8 (900ml) maintained at 37 ± 0.5
o
C.  
              Aliquots of dissolution media were withdrawn (10ml) at different intervals and content 
of Metoclopramide HCL was measured by determining absorbance at 273 nm. 10ml aliquot was 
withdrawn at the 0min, 1min, 2min, 3min .................to be continued at the 1min intervals and 
filter by whatmann filter paper. And analyzed at 273 nm using- visible spectrophotometer. 
 
 
 
STABILITY STUDIES
 
Definition  
Stability is defined as “the capacity of the drug product to remain within specifications 
established to ensure its identity, strength, quality and purity” (FDA 1987). 
Stability studies of pharmaceutical products were done as per ICH guidelines.  These 
studies are designed to increase the rate of chemical or physical degradation of the drug 
substance or product by using exaggerated storage conditions. Basically, there are two types of 
stability studies: 
1) Short -term stability studies 
2) Long - term stability studies 
Table 7.4 Stability conditions according to ICH guidelines 
Types Conditions Minimum time 
period    at 
submission 
(month) 
Temperature (
0 
C) Relative humidity 
(%) 
Short-term testing 40  2 75  5 6 
Long-term testing 25  2 60  5 12 
 
Method: 
Selected formulations were stored at different storage conditions at elevated temperatures 
such as 25
o
C± 2
0
C / 60% ± 5% RH, and 40
0
C ± 2
0
C/ 75% ± 5% RH for 90 days. The samples 
were withdrawn at intervals of 30 days and checked for physical changes, hardness, friability, 
drug content and percentage drug release. 
 
 
 
 
 
 
 
8. RESULTS AND DISCUSSION 
8.1 PREFORMULATION STUDIES 
Identification test for Metoclopramide HCL: 
            Identification of metoclopramide HCL was carried out by Melting Point, I.R. 
Spectroscopy, U.V. Spectroscopy, Identification test and solubility. 
A) Melting Point :  
      The melting point of the metoclopramide HCL was found to be 184
0
C, which complies 
with given in the official reference. 
B) I.R. Spectroscopy : 
Figure No. 8.1: FTIR Spectrum of Metoclopramide HCL 
 
 
FTIR spectrum of metoclopramide HCL as shown in figure no 8.1, showed all the peaks 
corresponding to the functional groups presents in the structure of metoclopramide HCL. 
 
 
 
 
 
 
 
 
 
 
Table No. 8.1: Interpretation of FTIR spectrum of Metoclopramide HCL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C) UV Spectroscopy : 
The λmax of pure Metoclopramide HCL was found to be 273 nm and 309 nm after 
scanning on the spectrophotometer, which complies with the reference spectra of 
metoclopramide HCL. (Fig. No.8.2) 
 
Figure No. 8.2: UV Spectrum of Metoclopramide HCL 
 
 
 
Transition IR Range Drug 
C=C 1500-1600 1593.20 
O-H 3400-2400 3394.72 
N-H 3100-3500 3199.91 
C-O 1300-1000 1141.86 
C-H 3000-2850 2943.37 
C=O 1680-1860 1818.87 
C-C 800-1300 837.11 
 
 
D) Identification Test : 
Identification test for Primary Aromatic Amines, the solution of drug was produced the red 
coloured precipitation after completion the reaction. It indicates the primary aromatic amine is 
present in the drug. (I.P.2007) 
E) Solubility : 
The Metoclopramide Hydrochloride was found to be freely soluble in water and alcohol. 
8.2 Drug and Excipients Compatibility Study : 
 Fourier transformed infra-red (FTIR) spectra of Metoclopramide HCL and the physical 
mixture of drug with excipients was taken by using IR Spectrophotometer. The scanning range 
was 450 - 4000 cm
-1
 and the resolution was 1 cm
-1
. The IR spectrum of pure drug and physical 
mixture of drug and excipients were studied. The characteristic absorption peaks of 
metoclopramide HCL and absorption peaks of physical mixture are corelates with each other. 
This indicate that the drug was compatible with the excipients. 
Figure No. 8.3: FTIR Spectrum of Drug with Crospovidone 
 
 
Figure No. 8.4: FTIR Spectrum of Drug with sodium starch glycolate 
 
 
 
 
Figure No. 8.5: FTIR Spectrum of Drug with Cross Carmellose Sodium 
 
Figure No. 8.6: FTIR Spectrum of Metoclopramide HCL with all excipients 
 
Table No. 8.2: FTIR spectra for the mixture of Metoclopramide HCL with various super 
disintegrants and with all excipients. 
 
Transit
ion 
IR Range Drug + 
Crospovidone 
Drug + sodium 
starch glycolate 
Drug + Cross 
Carmellose 
Sodium 
Drug + 
 all 
excipients 
 
C=C 1500-1600 1597.06 1597.06 - 1597.06 
C=O 1820-1660 - 1865.17 - 1865.20 
C-C 800-1300 839.03 839.03 837.11 837.10 
N-H 3300-3500 3199.91 3199.91 3196.06 3199.92 
C-O 1300-1000 1141.86 1155.36 1141.86 1141.85 
C-H 3000-2850 2943.37 2941.44 2943.37 2941.37 
 
 
Figure shows the IR spectra of pure Metoclopramide HCL and its physical mixture (1:1) with 
Crospovidone, Cross Carmellose Sodium, sodium starch glycolate and with all excipients. The 
IR spectra did not show any significant difference from those obtained for their physical mixture. 
These obtained results indicate that there was no positive evidence for the interaction between 
Metoclopramide HCL and super disintegrants or Metoclopramide HCL and excipients. These 
results clearly indicate the usefulness of the utilized super disintegrants for preparation of 
orodispersible tablet of pure Metoclopramide HCL. 
8.3 Standard Calibration Curve of Metoclopramide HCL : 
8.3.1 Preparation of standard calibration curve in hydrochloric acid buffer pH 1.2:  
             The standard calibration curve of Metoclopramide HCL was prepared by using 
hydrochloric acid buffer pH 1.2 as solvent. Standard calibration curve was obtained by plotting 
Absorbance Vs. Concentration. Table 8.3 shows the absorbance values of Metoclopramide HCL. 
The standard curve is shownin figure  8.7 the standard calibration curve shows the correlation 
coefficient of  0.9925. The curve was found to be linear in the concentration range of 2-10 µg/ml 
at 273.0 nm. Thus the standard curve followed the Beer- Lamberts Law. 
Table No. 8.3: Absorbance values for standard calibration curve of Metoclopramide HCL 
in hydrochloric acid buffer pH 1.2 
  
 
 
Sr.No. Concentration 
(µg/ml) 
Absorbance 
1 0 0 
2 2 0.097 
3 4 0.184 
4 6 0.238 
5 8 0.322 
6 10 0.399 
 
 
Fig. No. 8.7:  standard calibration curve for Metoclopramide HCL at 273.0 nm. in 
Hydrochloric acid buffer pH 1.2 
 
8.3.2 Calibration curve of Metoclopramide HCL in phosphate buffer pH 6.8: 
1) UV Spectra of drug in phosphate buffer pH 6.8:  
                   50 µg/ml solution of Metoclopramide HCL was prepared in phosphate buffer pH 6.8 
and was subjected to scanning under UV visible spectrophotometer, between the range 200-
400nm. The λmax was found to be at 272 nm. (Fig. 8.8) 
Figure No. 8.8: UV Spectrum of Metoclopramide HCL in phosphate buffer pH 6.8 
 
 
2) Preparation of standard calibration curve in phosphate buffer pH 6.8: 
                     The standard calibration curve of Metoclopramide HCL  was prepared by using 
phosphate buffer pH 6.8 as solvent. Standard calibration curve was obtained by plotting 
Absorbance Vs. Concentration. Table 8.4 shows the absorbance values of Metoclopramide 
Hydrochloride. The standard curve is shown in figure 8.9, the standard calibration curve shows 
 
 
the correlation coefficient of 0.9952. The curve was found to be linear in the concentration range 
of 2-10 µg/ml at 273.0 nm. Thus the standrad curve followed the Beer-Lamberts Law.  
Table No. 8.4: Absorbance values for standard calibration curve of         Metoclopramide 
HCL in phosphate buffer pH 6.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No. 8.9: Standard calibration curve of Metoclopramide HCL in pH 6.8 buffer. 
 
8.4 Pre-compression study of tablet blend: 
Nine formulations were prepared by using 2.6%, 4%, 5.3% concentration of super 
disintegration of superdisintegrants sodium starch glycolate, crospovidone and croscarmellose 
sodium. For each designed formulation, powder mixed blend of drug and excipients was 
prepared and evaluated for various parameters as follows. 
 
Sr. No. 
Concentration 
(µg/ml) 
Absorbance 
1 0 0 
2 2 0.081 
3 4 0.168 
4 6 0.248 
5 8 0.314 
6 10 0.378 
 
 
Angle of Repose (θ): 
 The angle of repose of various powders mixed blend, prepared with different 
superdisintegrants, was measured by cylinder method. Angle of repose was found in the range 
from 25.80 to 32.36 the good flowability of powder blend was also evidenced with angle of 
repose which is indicated a good flowability. The result are given in table no. 8.5 
 Table no. 8.5: Angle of Repose 
 
Bulk density: The bulk density of various powder mixed blends. Prepared with different 
superdisintegrants was measured by graduated cylinder. The bulk density was found in the range 
from 0.5 to 0.520. The result are given in table no. 8.6 
Table no. 8.6: Bulk Density 
Batch code Bulk density (gm/cm3) 
MF1  0.5 
MF2 0.510 
MF3 0.5 
MF4 0.5 
MF5 0.508 
MF6 0.520 
MF7 0.518 
MF8 0.519 
MF9 0.520 
Tapped density:The tapped density of various powder mixed blends prepared with different 
superdisintegrants, was measured by measuring cylinder. The tapped density was found in the 
range from 0.606 to 0.628. The result are given in table no. 8.7 
 
 
 
 
 
Batch code Angle of repose (θ) 
MF1  30.61 
MF2 32.12 
MF3 31.60 
MF4 29.60 
MF5 32.20 
MF6 32.36 
MF7 31.16 
MF8 25.80 
MF9 28.50 
 
 
Table no. 8.7: Tapped Density 
Batch code Tapped density 
(gm/cm
3
) 
MF1  0.608 
MF2 0.625 
MF3 0.625 
MF4 0.606 
MF5 0.617 
MF6 0.609 
MF7 0.621 
MF8 0.628 
MF9 0.627 
Compressibility Index:The compressibility index of various powder mixed blends prepared 
with different superdisintegrants using bulk density and tapped density data, compressibility 
index was calculated. It was found in the range 14.61 to 20.00. The result are given in table no. 
8.8 
Table no. 8.8: Compressibility Index 
Batch code Compressibility Index (%) 
MF1  17.76 
MF2 18.04 
MF3 20.00 
MF4 17.49 
MF5 17.66 
MF6 14.61 
MF7 16.58 
MF8 17.35 
MF9 16.08 
Hausner ratio: The Hausner ratio of various powder mixed blends prepared with different 
superdisintegrants, it was calculated by using bulk density and tapped density data. It was found 
in the range of 1.17 to 1.25. The result are given in table no. 8.9 
 
 
 
 
 
 
 
 
 
Table no .8.9: Hausner ratio 
Batch code Hausner ratio 
MF1  1.216 
MF2 1.225 
MF3 1.25 
MF4 1.212 
MF5 1.214 
MF6 1.171 
MF7 1.198 
MF8 1.210 
MF9 1.205 
 
8.5 Evaluation of orodispersible tablets of Metoclopramide HCl: 
Hardness:  Tablets were evaluated by using hardness tester. Hardness of the tablets was found in 
the range 1.90 to 2.20. The result are given in table no. 8.10 
Table no. 8.10: Hardness 
Batch code Hardness (kg/cm2) 
MF1  1.98 
MF2 1.98 
MF3 2.02 
MF4 1.95 
MF5 1.96 
MF6 2.0 
MF7 1.90 
MF8 2.20 
MF9 1.96 
Friability:  Tablets were evaluated by using Roche Friabilator and Friability of tablets was 
observed in acceptable range 0.48 to 0.81 (Less than 1%). The result are given in table no. 8.11 
 
Table no. 8.11: Friability 
Batch code Friability (%) 
MF1  0.650 
MF2 0.771 
MF3 0.589 
MF4 0.718 
MF5 0.819 
MF6 0.705 
MF7 0.489 
MF8 0.533 
MF9 0.788 
 
 
Thickness uniformity: Tablets were evaluated by using verniercaliper. The thickness of tablets 
wasfound to be exact 2.5 uniform thickness was obtained due to uniform die fill.  
 
Tablet no. 8.12: Thickness uniformity 
Batch code Thickness (mm) 
MF1  2.571 
MF2 2.552 
MF3 2.558 
MF4 2.573 
MF5 2.568 
MF6 2.568 
MF7 2.571 
MF8 2.574 
MF9 2.590 
Weight variation: Tablets were prepared using direct compression technique. Since the material 
was free flowing, tablets were obtained of uniforms weight due to uniform die fill. The tablets 
were obtained in the range with acceptable weight variations as per pharmacopoeia specifications 
less than 7.5%. The result are given in table no. 8.13  
 
Table no. 8.13: Weight variation 
Batch code Weight (mg) ± S.D Weight variation 
(7.5%) 
MF1  150.85 ±0.6 Passes 
MF2 149.25±0.4 Passes 
MF3 150.75±0.2 Passes 
MF4 148.20±0.3 Passes 
MF5 150.30 ±0.8 Passes 
MF6 151.48 ±0.4 Passes 
MF7 150.30 ±0.4 Passes 
MF8 149.60 ±0.2 Passes 
MF9 150.11±0.3 Passes 
In-vitro dispersion time: 
In-vitro dispersion time was measured by dropping a tablet into a petridish containing 10ml of 
phosphate buffer pH 6.8 solution at 37± 0.5
0
c. The dispersion time was found in the range 29 to 
45 for all batches. The batch MF9 showed the fast dispersion. The result are given in Table no. 
8.14   
 
 
 
Table no. 8.14: Dispersion Time 
Batch code Dispersion time (sec) 
MF1  35 
MF2 37 
MF3 40 
MF4 36 
MF5 42 
MF6 45 
MF7 33 
MF8 32 
MF9 29 
 
Figure No. 8.10 Dispersion Time 
 
Water absorption ratio: A piece of tissue paper folded twice was  placed in a small petri-dish 
(6.5cm)containing 6ml of water, a tablet was placed on the paper and the time forcomplete 
wetting was measured the wetted tablet was then weighed and thewater absorption ratio was 
calculated for each batch. The ratio was calculated for each batch. The ratios are given in table 
no. 8.15 
 
 
 
 
 
 
 
 
Table no. 8.15: Water absorption ratio 
Batch code Water absorption ratio 
±S.D 
MF1  62.65±5.90 
MF2 91.03±2.42 
MF3 67.76±6.04 
MF4 62.60±2.50 
MF5 67.56±5.40 
MF6 97.10±1.94 
MF7 83.81±5.77 
MF8 84.10±2.45 
MF9 61.65±5.90 
Disintegration time:  
Tablets were evaluated for disintegration time in the disintegration test apparatus (I.P) 
The disintegration time was found in the range 26 to 36 for all the batches. The batchMF9 
showed the fastest disintegration. The result are given in table no. 8.16 
Table no. 8.16: Disintegration Time 
Batch code Disintegration time 
(sec) 
MF1  31 
MF2 33 
MF3 32 
MF4 31 
MF5 32 
MF6 36 
MF7 28 
MF8 27 
MF9 26 
 
Figure No. 8.11 Disintegration Time 
 
 
 
 
Content uniformity: 
The results for content uniformity are presented in table no. 8.17 The results showed drug 
content were lying within the limits. The assay limit of Metoclopramide HCLtablets as per IP is 
90-110%. The assays of the tablets were carried out as a process given in IP and data table are as 
follows. 
                                                      Table no. 8.17: Content uniformity 
Sr.no Batch code Content uniformity 
(%) 
1 MF1  98.96 
2 MF2 99.02 
3 MF3 100.30 
4 MF4 99.16 
5 MF5 97.91 
6 MF6 98.95 
7 MF7 99.03 
8 MF8 99.30 
9 MF9 98.93 
 
In-vitro release studies: 
The Comparative analysis of each formulation was based on in vitro kinetic parameters, 
which elucidated the release profile. The in-vitro drug release of  orodispersible tablets of 
Metoclopramide HCL for all formulation is given as follows. 
In vitro drug release studies details: 
Apparatus used                         : USP II dissolution test apparatus 
Dissolution medium                  : 6.8Buffer 
 
 
Dissolution medium volume     : 900 ml 
Temperature                              : 37±0.5ºC 
Speed of basket paddle             : 50 rpm 
Sampling intervals                    : 1 min 
Sample withdrawn                    : 10 ml 
Absorbance measured               : 273 nm 
In-vitro release studies of batch MF1 in  pH 6.8 buffer 
               Table no. 8.18 In-vitro release studies of batch MF1 in  pH 6.8 buffer 
Sr.no Time (min) Percent drug 
release 
1 0 0 
2 1 16.39 
3 2 32.62 
4 3 56.39 
5 4 69.53 
6 5 79.36 
7 6 94.35 
 
Figure No. 8.12: In-vitro release studies of batch MF1 in  pH 6.8 buffer 
 
 
 
 
 
 
 
 
In-vitro release studies of batch MF2 in pH 6.8 
Table No. 8.19: In-vitro release studies of batch MF2 in pH 6.8 
Sr.no Time (min) Percent drug 
release 
1 0 00 
2 1 22.39 
3 2 39.62 
4 3 52.39 
5 4 76.56 
6 5 93.65 
 
 
Figure No.8.13: In-vitro release studies of batch MF2 in pH 6.8 
 
 
 
 
 
 
 
 
 
 
In-vitro release studies of batch MF3 in pH 6.8 
Table No. 8.20: In-vitro release studies of batch MF3 in pH 6.8 
Sr.no Time (min) Percent drug 
release 
1 0 00 
2 1 22.39 
3 2 49.62 
4 3 78.39 
5 4 92.50 
6 5 99.79 
 
Figure No.8.14: In-vitro release studies of batch MF3 in pH 6.8 
 
 
 
 
 
 
 
 
 
 
In-vitro release studies of batch MF4 in pH 6.8 
Table No. 8.21: In-vitro release studies of batch MF4 in pH 6.8 
Sr.no Time (min) Percent drug 
release(%) 
1 0 00 
2 1 20.96 
3 2 32.15 
4 3 55.09 
5 4 77.59 
6 5 85.35 
7 6 91.35 
8 7 99.25 
 
Figure No.8.15: In-vitro release studies of batch MF4 in pH 6.8 
 
 
 
 
 
 
 
 
 
 
In-vitro release studies of batch MF5 in pH 6.8 
Table No. 8.22: In-vitro release studies of batch MF5 in pH 6.8 
Sr.no Time (min) Percent drug 
release(%) 
1 0 00 
2 1 20.96 
3 2 32.15 
4 3 55.09 
5 4 77.59 
6 5 88.62 
7 6 98.96 
 
 
Figure No. 8.16: In-vitro release studies of batch MF5 in pH 6.8 
 
 
 
 
 
 
 
In-vitro release studies of batch MF6 in pH 6.8 
Table No. 8.23: In-vitro release studies of batch MF6 in pH 6.8 
Sr.no Time (min) Percent drug 
release 
1 0 00 
2 1 22.39 
3 2 39.62 
4 3 68.39 
5 4 77.5 
6 5 92.36 
 
Figure No.8.17: In-vitro release studies of batch MF6 in pH 6.8 
 
 
 
 
 
 
 
In-vitro release studies of batchMF7 in pH 6.8 
 
 
Table No. 8.24: In-vitro release studies of batchMF7 in pH 6.8 
Sr.no Time (min) Percent drug 
release 
1 0 0 
2 1 21.51 
3 2 42.70 
4 3 62.35 
5 4 97.15 
 
Figure No.8.18: In-vitro release studies of batchMF7 in pH 6.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In-vitro release studies of batch MF8 in pH 6.8 
Table No. 8.25: In-vitro release studies of batch MF8 in pH 6.8 
Sr.no Time (min) Percent drug 
release 
1 0 0 
2 1 32.39 
3 2 53.58 
4 3 75.86 
5 4 98.97 
 
 
 
 
 
Figure No.8.19: In-vitro release studies of batch MF8 in pH 6.8 
 
 
 
 
 
 
 
In-vitro release studies of batch MF9 in pH 6.8 
Table No. 8.26: In-vitro release studies of batch MF9 in pH 6.8 
Sr.no Time (min) Percent drug 
release 
1 0 00 
2 1 52.63 
3 2 72.63 
4 3 99.60 
 
Figure No.8.20: In-vitro release studies of batch MF9 in pH 6.8 
 
 
 
 
 
 
 
 
 
 
 
COMPARATIVE IN VITRO DRUG RELEASE PROFILE OF ORODISPERSIBLE 
TABLETS OF METOCLOPRAMIDE HCL IN pH 6.8 BUFFER 
Table No. 8.27: Comparative in-vitro drug release profile of all batches 
 
                       From the above observation we can conclude that, as concentration of sodium 
starch glycolate, crospovidone, and cross carmellose sodium increase the disintegration time also 
increase. But the superdisintegrant cross carmellose sodium gives the minimum disintegrating 
time as compare to sodium starch glycolate or crospovidone. In the batch of cross carmellose 
sodium gives minimum disintegrating time and drug release in 3mins. at the concentration of 
5.3% of cross carmellose sodium. And the batch of sodium starch glycolate and crospovidone (at 
the same conc. of superdisintegration i.e. 5.3%) gives the more disintegration time. 
 
 
 
 
 
Sr. 
no 
Time 
(MIN) 
Percent drug release 
MF1 MF2 MF3 MF4 MF5 MF6 MF7 MF8 MF9 
1 0 00 00 00 00 00 00 00 00 00 
2 1 16.39 22.39 22.39 20.96 20.96 22.39 21.51 32.39 52.63 
3 2 32.62 39.62 49.62 32.15 32.15 39.62 42.70 53.58 72.63 
4 3 56.39 52.39 78.39 55.09 55.09 68.39 62.35 75.86 99.60 
5 4 69.53 76.56 92.50 77.59 77.59 77.5 97.15 98.97  
6 5 79.36 93.65 99.79 85.35 88.62 92.36    
7 6 94.35   91.35 98.96     
8 7    99.25      
 
 
Figure No. 8.21: Comparative in vitro drug release profile of batches MF1 to MF4 
 
 
 
Figure No. 8.22: Comparative in vitro drug release profile of batches MF5 to MF9 
 
 
STABILITY STUDIES: 
Table No. 8.28: Showing the Stability Studies of Formulation MF9 at 25
o
C ± 2
o
C and 60% 
RH ± 5% RH 
Time (days) Drug content(%) Hardness (Kg/cm
2
) Friability (%) 
30 98.41 1.94 ±0.12 0.58 ±0.012 
60 97.53 1.90 ±0.11 0.56  ±0.012 
90 96.87 1.89 ±0.11 0.55  ±0.012 
 
 
 
Table No. 8.29 Showing the Stability Studies of Formulation MF9 at 40oC ± 2oC and 75% RH 
± 5% RH 
Time (days) Drug content(%) Hardness (Kg/cm
2
) Friability(%) 
30 98.25 1.94 ±0.12 0.58  ±0.012 
60 97.23 1.89 ±0.11 0.55 ±0.012 
90 96.47 1.88 ±0.10 0.54  ±0.013 
  
                     Stability studies were carried out on optimized formulation (MF9) as per ICH 
guidelines. There was not much variation in the tablets at all the temperature conditions. There 
was no significant changes in drug content, physical stability, hardness, friability, drug release 
for the optimized formulation MF9 after 90 days at 25
o
C± 2
0
C / 60% ± 5% RH,  and 40
0
C ± 2
0
 / 
75% ± 5% RH. 
 
Figure No. 8.23: showing stability study for formulation MF9 at various temperature 
 
 
 
 
9. SUMMARY AND CONCLUSION 
 9.1 Summary: 
             Metoclopramide hydrochloride is Antiemetics, Dopamine Antagonists, Prokinetic 
Agents used to treat nausea and vomiting, it blocks the D2 receptors in the Chemoreceptor 
Trigger Zone (CTZ) in the central nervous system. It is effective and popular drug for many 
types of vomiting. Gastrokinetic: to accelerate gastric emptying, Dyspepsia, Gastroesophageal 
reflux disease (GERD). On high dose it also shows the 5-HT3 receptor antagonist. 
Metoclopramide hydrochloride may used to be treat chemotherapy induced emesis.                                
              The aim of present work was to prepare a suitable orodispersible tablet of 
Metoclopramide hydrochloride; once a day Metoclopramide hydrochloride dosage form could 
reduce the dosing frequency and improve patient compliance. 
              Sodium starch glycolate, crospovidone, cross carmellose sodium are use as 
superdisintegrant at minimum to maximum quantity which give better disintegration time with 
better releasing time was studied. Initially study gives the report that as we increase the 
concentration superdisintegrating agents, the disintegrating time and in-vitro drug release are 
also increases.                               
               In the study all the formulation were subjected to physical parameters of tablets, like 
hardness, friability, weight variation, drug content of Metoclopramide hydrochloride. All the 
formulations resulted in acceptable limit except formulation MF3 and MF8 for hardness test 
marginally deviated. The final batch MF9 (contained Cross Carmellose Sodium 5.3%) can be 
considered as optimized batch as it has the disintegration time is minimum (26 sec) seems to be 
most promising formulation which gives the release up to 99.60% in 3min. 
              The drug-excipients interaction studies were carried out by FTIR. No significant 
interaction of drug with excipients was observed. During stability studies, no significant 
variation in drug release was observed, indicating that formulation batch MF9 was stable over 
the chosen condition for 3 months. 
               The optimized formulation batch MF9 showed better drug release profile with other 
formulations. 
 
 
9.2 Conclusion:  
             From the present study carried out on metoclopramide HCL orodispersible tablet using 
by direct compression method, the following conclusion can be drawn. 
             The total weight of MF9 batch was 150 mg contained metoclopramide HCL-6.6%, 
croscarmellose sodium-5.3%, microcrystalline cellulose-33.3%, aspartame-4%, magnesium 
stearate-1%, talc-0.6%, aerosil-0.3%, pineapple flavor-0.6%, mannitol-48%.  
            The Prefromulation study gives the following information of optimize batch Angle of 
Repose-28
0
.50
‟
 Bulk density-0.520, Tapped density-0.627, Compressibility Index-16.08 good to 
flow, Hausner ratio-1.205. 
             Post parameter evaluation of tablets Hardness-1.96, Friability-0.788, Thickness-2.590, 
Weight variation-150.11±, Dispersion time-29 sec, Water absorption ratio-61.65, Disintegration 
time-26 sec, Content uniformity-98.93%, In-vitro drug release studies- in 3 min.  
             If the concentration of croscarmellose sodium is increases it gives quick the 
disintegration and dissolution was observed. So the results give information that   Disintegration 
time in 26 sec and dissolution in 3 min. Croscarmellose sodium is the optimize batch on basis of 
disintegration time and in-vitro drug release. 
             The optimized formulation of batch MF9 gave the best in-vitro release of 99.60% in 
3min in phosphate buffer pH 6.8. The release of drug followed matrix diffusion mechanism. 
              Our objective to cost effective orodispersible tablet by direct compression quickly 
disperse in oral cavity and it definitely gives the fast release action for its antiemetic activity. 
Fast disintegration of tablets formulated in this investigation may be help in administration of 
metoclopramide HCL in a palatable form without water during emesis. Formulation MF9 gives 
the quick disintegration and better drug release. Hence it can be concluded that the formulation 
MF9 is a stable and effective for quick action and it is alternative to the conventional tablets. 
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